SB 423: Surplus household consumer product waste: management.
- Session Year: 2015-2016
- House: Senate
- Latest Version Date: 2016-09-28
Existing law requires the Department of Resources Recycling and Recovery, in consultation with the Department of Toxic Substances Control, to develop and implement a public information program to provide uniform and consistent information on the proper disposal of hazardous substances found in and around homes. Existing law provides for regulation of the disposition of hazardous waste by the Department of Toxic Substances Control.
This bill would require the Department of Toxic Substances Control to convene a Retail Waste Working Group, as prescribed, to consider and make findings and recommendations relating to requirements for the management of surplus household consumer products, waste reduction opportunities for those products, and waste management requirements, as specified. The bill would require the working group to report these findings and recommendations to the Legislature by June 1, 2017.
Existing law requires the Department of Resources Recycling and Recovery, in consultation with the Department of Toxic Substances Control, to develop and implement a public information program to provide uniform and consistent information on the proper disposal of hazardous substances found in and around homes. Existing law provides for regulation of the disposition of hazardous waste by the Department of Toxic Substances Control.
This bill would require the Department of Toxic Substances Control to convene a Retail Waste Working Group, as prescribed, to consider and make findings and recommendations relating to requirements for the management of surplus household consumer products, waste reduction opportunities for those products, and waste management requirements, as specified. The bill would require the working group to report these findings and recommendations to the Legislature by June 1, 2017.
Existing law requires the Department of Resources Recycling and Recovery, in consultation with the Department of Toxic Substances Control, to develop and implement a public information program to provide uniform and consistent information on the proper disposal of hazardous substances found in and around homes. Existing law provides for regulation of the disposition of hazardous waste by the Department of Toxic Substances Control.
This bill would require the Department of Toxic Substances Control to convene a Retail Waste Working Group, as prescribed, to consider and make findings and recommendations relating to requirements for the management of surplus household consumer products, waste reduction opportunities for those products, and waste management requirements, as specified. The bill would require the working group to report these findings and recommendations to the Legislature by June 1, 2017.
Existing law requires the Department of Resources Recycling and Recovery, in consultation with the Department of Toxic Substances Control, to develop and implement a public information program to provide uniform and consistent information on the proper disposal of hazardous substances found in and around homes. Existing law provides for regulation of the disposition of hazardous waste by the Department of Toxic Substances Control.
This bill would require the Department of Toxic Substances Control to convene a Retail Waste Working Group, as prescribed, to consider and make findings and recommendations relating to requirements for the management of surplus household consumer products that are wastes, products, waste reduction opportunities for consumer those products, and hazardous waste management requirements in the retail industry, requirements, as specified. The bill would require the working group to report these findings and recommendations to the Legislature by June 1, 2017.
Existing law, the Medical Waste Management Act, administered by the State Department of Public Health, regulates the management, handling, and disposal of medical waste, as defined, including pharmaceutical waste. Existing law requires a person generating or treating medical waste to ensure that the medical waste is treated by a specified method, thereby rendering it a solid waste, before disposal, except in prescribed circumstances. Existing law requires the Department of Resources Recycling and Recovery, in consultation with the Department of Toxic Substances Control, to develop and implement a public information program to provide uniform and consistent information on the proper disposal of hazardous substances found in and around homes. Existing law also provides for regulation of the disposition of hazardous waste by the Department of Toxic Substances Control. A violation of these provisions is a crime.
This bill, until January 1, 2022, would require a pharmaceutical that is offered for sale without a prescription, upon discard, to be managed in accordance the hazardous waste provisions if the pharmaceutical is a hazardous waste, or, if the pharmaceutical is not a hazardous waste, in accordance with the above-described medical waste provisions or specified solid waste provisions.
Because a violation of these provisions would be a crime, this bill would impose a state-mandated local program.
This bill would require the Department of Toxic Substances Control to convene a Retail Waste Working Group, as prescribed, to identify regulatory and policy directives that need clarification or specification when applied to consumer products and to adopt consensus recommendations to facilitate and increase sustainable practices and waste reduction opportunities for consumer products and to encourage safe and efficient options for managing the flow of surplus household consumer products through the reverse supply chain. consider and make recommendations relating to requirements for the management of consumer products that are wastes, waste reduction opportunities for consumer products, and hazardous waste management requirements in the retail industry, as specified. The bill would require the working group to identify a list of issues for discussion and resolution by March 1, 2017, and to report consensus these recommendations to the Legislature by June 1, 2017.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Medical Waste Management Act, administered by the State Department of Public Health, regulates the management, handling, and disposal of medical waste, as defined, including pharmaceutical waste. Existing law requires a person generating or treating medical waste to ensure that the medical waste is treated by a specified method, thereby rendering it a solid waste, before disposal, except in prescribed circumstances. Existing law also provides for regulation of the disposition of hazardous waste by the Department of Toxic Substances Control. A violation of these provisions is a crime.
This bill, until January 1, 2022, would establish criteria to be followed for the handling and management of retail nonprescription pharmaceutical surplus products, as defined, if a reasonable determination for reuse has been made or when a reasonable determination for reuse cannot be made but the product has been recalled as required by law. The bill would authorize the State Department of Public Health to adopt regulations as deemed necessary to establish standards for the proper and safe handling of retail nonprescription pharmaceutical surplus products.
This bill, until January 1, 2022, would require a pharmaceutical that is offered for sale without a prescription, upon discard, to be managed in accordance the hazardous waste provisions if the pharmaceutical is a hazardous waste, or, if the pharmaceutical is not a hazardous waste, in accordance with the above-described medical waste provisions or specified solid waste provisions.
Because a violation of these provisions would be a crime, this bill would impose a state-mandated local program.
This bill would require the Department of Toxic Substances Control to convene a Retail Waste Working Group, as prescribed, to identify regulatory and policy directives that need clarification or specification when applied to consumer products and to adopt consensus recommendations to facilitate and increase sustainable practices and waste reduction opportunities for consumer products and to encourage safe and efficient options for managing the flow of surplus household consumer products through the reverse supply chain. The bill would require the working group to identify a list of issues for discussion and resolution by March 1, 2017, and to report consensus recommendations to the Legislature by June 1, 2017.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
This bill would declare that it is to take effect immediately as an urgency statute.
Existing law, the Medical Waste Management Act, administered by the State Department of Public Health, regulates the management, handling, and disposal of medical waste, as defined, including pharmaceutical waste. Existing law also provides for the disposition of hazardous waste. waste by the Department of Toxic Substances Control. A violation of these provisions is a crime.
This bill, until January 1, 2022, would establish criteria to be followed for the handling and management of retail nonprescription pharmaceutical surplus products, as defined, if a reasonable determination for reuse has been made or when a reasonable determination for reuse cannot be made but the product has been recalled as required by law. The bill would authorize the State Department of Public Health to adopt regulations as deemed necessary to establish standards for the proper and safe handling of retail nonprescription pharmaceutical surplus products.
Because a violation of these provisions would be a crime, this bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
This bill would declare that it is to take effect immediately as an urgency statute.
Existing law, the Medical Waste Management Act, administered by the State Department of Public Health, regulates the management, handling, and disposal of medical waste, as defined, including pharmaceutical waste. For purposes of that act, pharmaceutical waste is defined as a prescription or over-the counter human or veterinary drug, as specified, that is waste, as defined, but excludes from that definition certain pharmaceuticals being sent out of state to a reverse distributor, or being sent by a reverse distributor offsite for treatment and disposal, as prescribed. Existing law also provides for the disposition of hazardous waste. A violation of these provisions is a crime.
This bill would additionally exclude from the definition of pharmaceutical waste, for purposes of regulation under the act, any over-the-counter human or veterinary drug or dietary supplement that is, among other things, characterized and managed as a hazardous or solid waste and, with respect to an over-the-counter human or veterinary drug, is not disposed of on land within the state.
This bill, until January 1, 2022, would establish criteria to be followed for the handling and management of retail nonprescription pharmaceutical surplus products, as defined, if a reasonable determination for reuse has been made or when a reasonable determination for reuse cannot be made but the product has been recalled as required by law. The bill would authorize the State Department of Public Health to adopt regulations as deemed necessary to establish standards for the proper and safe handling of retail nonprescription pharmaceutical surplus products.
Because a violation of these provisions would be a crime, this bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
This bill would declare that it is to take effect immediately as an urgency statute.
The existing
Existing law, the Medical Waste Management Act, administered by the State Department of Public Health, regulates the management, handling, and disposal of medical waste, as defined, including pharmaceutical waste. For purposes of that act, pharmaceutical waste is defined as a prescription or over-the counter human or veterinary drug, as specified, that is waste, as defined, but excludes from that definition certain pharmaceuticals being sent out of state to a reverse distributor, or being sent by a reverse distributor offsite for treatment and disposal, as prescribed.
This bill would additionally exclude from the definition of pharmaceutical waste, for purposes of regulation under the act, any over-the-counter human or veterinary drug or dietary supplement that is, among other things, characterized and managed as a hazardous or solid waste and, with respect to an over-the-counter human or veterinary drug, is not disposed of on land within the state.
This bill would declare that it is to take effect immediately as an urgency statute.
The existing law, the Medical Waste Management Act, administered by the State Department of Public Health, regulates the management, handling, and disposal of medical waste, as defined, including pharmaceutical waste. For purposes of that act, pharmaceutical waste is defined as a prescription or over-the counter human or veterinary drug, as specified, that is waste, as defined, but excludes from that definition certain pharmaceuticals being sent out of state to a reverse distributor, or being sent by a reverse distributor offsite for treatment and disposal, as prescribed.
This bill would additionally exclude from the definition of pharmaceutical waste, for purposes of regulation under the act, any over-the-counter human or veterinary drug or dietary supplement that is, among other things, characterized and managed as a hazardous or solid waste and, with respect to an over-the-counter human or veterinary drug, is not disposed of on land within the state.
(a)The department shall convene a Retail Waste Working Group comprised of representatives of large retailers, small retailers, district attorneys, certified unified program agencies, nongovernment organizations, local governments, other relevant state agencies as determined by the department, manufacturers, reverse distributors, and other stakeholders to consider and make findings and recommendations on the following:
(1)Regulatory and statutory requirements that may be considered confusing or may need clarification or specification when applied to the overall management by manufacturer, distributor, supplier, vendor, retail, and reverse logistics facilities of surplus household consumer products, including products that can be considered hazardous waste or pharmaceutical waste once a waste determination is made.
(2)Statutory or regulatory recommendations to facilitate and increase the donation, liquidation, and sale of surplus household consumer products, and waste reduction opportunities for those products, and to clarify waste management requirements to encourage the management of surplus household consumer products by manufacturer, distributor, supplier, vendor, retail, and reverse logistics facilities in a manner that is protective of public health and the environment.
(b)For purposes of this section, surplus household consumer product means a household consumer product that cannot or will not be sold to a consumer through that products primary market.
(c)By June 1, 2017, the Retail Waste Working Group shall report the findings and recommendations made pursuant to subdivision (a) to the Legislature.
(a)The department shall convene a Retail Waste Working Group comprised of representatives of large retailers, small retailers, district attorneys, certified unified program agencies, nongovernment organizations, local governments, other relevant state agencies as determined by the department, manufacturers, reverse distributors, and other stakeholders to consider and make findings and recommendations on the following:
(1)Regulatory and statutory requirements that may be considered confusing or may need clarification or specification when applied to the overall management by manufacturer, distributor, supplier, vendor, retail, and reverse logistics facilities of surplus household consumer products, including products that can be considered hazardous waste or pharmaceutical waste once a waste determination is made.
(2)Statutory or regulatory recommendations to facilitate and increase the donation, liquidation, and sale of surplus household consumer products, and waste reduction opportunities for those products, and to clarify waste management requirements to encourage the management of surplus household consumer products by manufacturer, distributor, supplier, vendor, retail, and reverse logistics facilities in a manner that is protective of public health and the environment.
(b)For purposes of this section, surplus household consumer product means a household consumer product that cannot or will not be sold to a consumer through that products primary market.
(c)By June 1, 2017, the Retail Waste Working Group shall report the findings and recommendations made pursuant to subdivision (a) to the Legislature.
(a)The department shall convene a Retail Waste Working Group comprised of representatives of large retailers, small retailers, district attorneys, certified unified program agencies, nongovernment organizations, local governments, other relevant state agencies as determined by the department, manufacturers, reverse distributors, and other stakeholders to consider and make findings and recommendations on the following:
(1)Regulatory and statutory requirements that may be considered confusing or may need clarification or specification when applied to the overall management by manufacturer, distributor, supplier, vendor, retail, and reverse logistics facilities of surplus household consumer products, including products that can be considered hazardous waste or pharmaceutical waste once a waste determination is made.
(2)Statutory or regulatory recommendations to facilitate and increase the donation, liquidation, and sale of surplus household consumer products products, and waste reduction opportunities for those products products, and to clarify waste management requirements to encourage the management of surplus household consumer products by manufacturer, distributor, supplier, vendor, retail, and reverse logistics facilities in a manner that is protective of public health and the environment.
(b)For purposes of this section, surplus household consumer product means a household consumer product that cannot or will not be sold to a consumer through that products primary market.
(c)By June 1, 2017, the Retail Waste Working Group shall report the findings and recommendations made pursuant to subdivision (a) to the Legislature.
(a)The department shall convene a Retail Waste Working Group comprised of representatives of large retailers, small retailers, district attorneys, certified unified program agencies, nongovernment organizations, other relevant state agencies as determined by the department, manufacturers, reverse distributors, and other stakeholders to consider and make findings and recommendations on the following:
(1)Regulatory and policy statutory requirements that may be considered confusing or may need clarification or specification when applied to the overall management by manufacturer, distributor, supplier, vendor, retail, and reverse logistics facilities of surplus household consumer products that are wastes, products, including those products that are can be considered hazardous wastes when the waste or pharmaceutical waste once a waste determination is made.
(2)Consensus policy or Statutory or regulatory recommendations to facilitate and increase the donation, liquidation, and sale of surplus household consumer products and waste reduction opportunities for consumer those products and to clarify hazardous waste management requirements in the retail industry to encourage safe and efficient options for managing waste and the management of surplus household consumer products. products by manufacturer, distributor, supplier, vendor, retail, and reverse logistics facilities in a manner that is protective of public health and the environment.
(b)For purposes of this section, surplus household consumer product means a household consumer product that cannot or will not be sold to a consumer through that products primary market.
(b)
(c)By June 1, 2017, the Retail Waste Working Group shall report the findings and recommendations made pursuant to subdivision (a) to the Legislature.
(a)The department shall convene a Retail Waste Working Group comprised of representatives of large retailers, small retailers, district attorneys, certified unified program agencies, nongovernment organizations, other relevant state agencies as determined by the department, manufacturers, reverse distributors, and other stakeholders to consider and make recommendations on the following:
(1)Regulatory and policy requirements that may be considered confusing or may need clarification or specification when applied to the overall management of consumer products that are wastes, including those that are considered hazardous wastes when the waste determination is made.
(2)Consensus policy or regulatory recommendations to facilitate and increase waste reduction opportunities for consumer products and to clarify hazardous waste management requirements in the retail industry to encourage safe and efficient options for managing waste and surplus consumer products.
(b)By June 1, 2017, the Retail Waste Working Group shall report the recommendations made pursuant to subdivision (a) to the Legislature.
SECTION 1.Section 118215 of the Health and Safety Code is amended to read:118215.(a)Except as provided in subdivisions (b) and (c) and Section 118216, a person generating or treating medical waste shall ensure that the medical waste is treated by one of the following methods, thereby rendering it solid waste, as defined in Section 40191 of the Public Resources Code, before disposal:
(1)(A)Incineration at a permitted medical waste treatment facility in a controlled-air, multichamber incinerator, or other method of incineration approved by the department that provides complete combustion of the waste into carbonized or mineralized ash.
(B)Treatment with an alternative technology approved pursuant to paragraph (3), which, due to the extremely high temperatures of treatment in excess of 1,300 degrees Fahrenheit, has received express approval from the department.
(2)Steam sterilization at a permitted medical waste treatment facility or by other sterilization, in accordance with all of the following operating procedures for steam sterilizers or other sterilization:
(A)Standard written operating procedures shall be established for biological indicators, or for other indicators of adequate sterilization approved by the department, for each steam sterilizer, including time, temperature, pressure, type of waste, type of container, closure on container, pattern of loading, water content, and maximum load quantity.
(B)Recording or indicating thermometers shall be checked during each complete cycle to ensure the attainment of 121 degrees centigrade (250 degrees Fahrenheit) for at least one-half hour, depending on the quantity and density of the load, to achieve sterilization of the entire load. Thermometers, thermocouples, or other monitoring devices identified in the facility operating plan shall be checked for calibration annually. Records of the calibration checks shall be maintained as part of the facilitys files and records for a period of two years or for the period specified in the regulations.
(C)Heat-sensitive tape, or another method acceptable to the enforcement agency, shall be used on each biohazard bag or sharps container that is processed onsite to indicate that the waste went through heat treatment. If the biohazard bags or sharps containers are placed in a large liner bag within the autoclave for treatment, heat-sensitive tape or another method acceptable to the enforcement agency only needs to be placed on the liner bag and not on every hazardous waste bag or sharps container being treated.
(D)The biological indicator Geobacillus stearothermophilus, or other indicator of adequate sterilization as approved by the department, shall be placed at the center of a load processed under standard operating conditions at least monthly to confirm the attainment of adequate sterilization conditions.
(E)Records of the procedures specified in subparagraphs (A), (B), and (D) shall be maintained for a period of not less than two years.
(3)(A)Other alternative medical waste treatment methods that are both of the following:
(i)Approved by the department.
(ii)Result in the destruction of pathogenic microorganisms.
(B)Any alternative medical waste treatment method proposed to the department shall be evaluated by the department and either approved or rejected pursuant to the criteria specified in this subdivision.
(b)Fluid blood or fluid blood products may be discharged to a public sewage system without treatment if its discharge is consistent with waste discharge requirements placed on the public sewage system by the California regional water quality control board with jurisdiction.
(c)(1)A medical waste that is a biohazardous laboratory waste, as defined in subparagraph (B) of paragraph (1) of subdivision (b) of Section 117690, may be treated by a chemical disinfection if the waste is liquid or semiliquid and the chemical disinfection method is recognized by the National Institutes of Health, the Centers for Disease Control and Prevention, or the American Biological Safety Association, and if the use of chemical disinfection as a treatment method is identified in the sites medical waste management plan.
(2)If the waste is not treated by chemical disinfection, in accordance with paragraph (1), the waste shall be treated by one of the methods specified in subdivision (a).
(3)Following treatment by chemical disinfection, the medical waste may be discharged to the public sewage system if the discharge is consistent with waste discharge requirements placed on the public sewage system by the California regional water quality control board, and the discharge is in compliance with the requirements imposed by the owner or operator of the public sewage system. If the chemical disinfection of the medical waste causes the waste to become a hazardous waste, the waste shall be managed in accordance with the requirements of Chapter 6.5 (commencing with Section 25100) of Division 20.
(d)This section shall remain in effect only until January 1, 2022, and as of that date is repealed, unless a later enacted statute, that is enacted before January 1, 2022, deletes or extends that date.
SEC. 2.Section 118215 is added to the Health and Safety Code, to read:118215.(a)Except as provided in subdivisions (b) and (c), a person generating or treating medical waste shall ensure that the medical waste is treated by one of the following methods, thereby rendering it solid waste, as defined in Section 40191 of the Public Resources Code, before disposal:
(1)(A)Incineration at a permitted medical waste treatment facility in a controlled-air, multichamber incinerator, or other method of incineration approved by the department that provides complete combustion of the waste into carbonized or mineralized ash.
(B)Treatment with an alternative technology approved pursuant to paragraph (3), which, due to the extremely high temperatures of treatment in excess of 1,300 degrees Fahrenheit, has received express approval from the department.
(2)Steam sterilization at a permitted medical waste treatment facility or by other sterilization, in accordance with all of the following operating procedures for steam sterilizers or other sterilization:
(A)Standard written operating procedures shall be established for biological indicators, or for other indicators of adequate sterilization approved by the department, for each steam sterilizer, including time, temperature, pressure, type of waste, type of container, closure on container, pattern of loading, water content, and maximum load quantity.
(B)Recording or indicating thermometers shall be checked during each complete cycle to ensure the attainment of 121 degrees centigrade (250 degrees Fahrenheit) for at least one-half hour, depending on the quantity and density of the load, to achieve sterilization of the entire load. Thermometers, thermocouples, or other monitoring devices identified in the facility operating plan shall be checked for calibration annually. Records of the calibration checks shall be maintained as part of the facilitys files and records for a period of two years or for the period specified in the regulations.
(C)Heat-sensitive tape, or another method acceptable to the enforcement agency, shall be used on each biohazard bag or sharps container that is processed onsite to indicate that the waste went through heat treatment. If the biohazard bags or sharps containers are placed in a large liner bag within the autoclave for treatment, heat-sensitive tape or another method acceptable to the enforcement agency only needs to be placed on the liner bag and not on every hazardous waste bag or sharps container being treated.
(D)The biological indicator Geobacillus stearothermophilus, or other indicator of adequate sterilization as approved by the department, shall be placed at the center of a load processed under standard operating conditions at least monthly to confirm the attainment of adequate sterilization conditions.
(E)Records of the procedures specified in subparagraphs (A), (B), and (D) shall be maintained for a period of not less than two years.
(3)(A)Other alternative medical waste treatment methods that are both of the following:
(i)Approved by the department.
(ii)Result in the destruction of pathogenic microorganisms.
(B)Any alternative medical waste treatment method proposed to the department shall be evaluated by the department and either approved or rejected pursuant to the criteria specified in this subdivision.
(b)Fluid blood or fluid blood products may be discharged to a public sewage system without treatment if its discharge is consistent with waste discharge requirements placed on the public sewage system by the California regional water quality control board with jurisdiction.
(c)(1)A medical waste that is a biohazardous laboratory waste, as defined in subparagraph (B) of paragraph (1) of subdivision (b) of Section 117690, may be treated by a chemical disinfection if the waste is liquid or semiliquid and the chemical disinfection method is recognized by the National Institutes of Health, the Centers for Disease Control and Prevention, or the American Biological Safety Association, and if the use of chemical disinfection as a treatment method is identified in the sites medical waste management plan.
(2)If the waste is not treated by chemical disinfection, in accordance with paragraph (1), the waste shall be treated by one of the methods specified in subdivision (a).
(3)Following treatment by chemical disinfection, the medical waste may be discharged to the public sewage system if the discharge is consistent with waste discharge requirements placed on the public sewage system by the California regional water quality control board, and the discharge is in compliance with the requirements imposed by the owner or operator of the public sewage system. If the chemical disinfection of the medical waste causes the waste to become a hazardous waste, the waste shall be managed in accordance with the requirements of Chapter 6.5 (commencing with Section 25100) of Division 20.
(d)This section shall become operative on January 1, 2022.
SEC. 3.Section 118216 is added to the Health and Safety Code, to read:118216.(a)Notwithstanding Section 117690, a pharmaceutical that is offered for sale without a prescription shall, upon discard, be managed in accordance with Chapter 6.5 (commencing with Section 25100) of Division 20 if it is a hazardous waste as defined in Section 25117 and implementing regulations. If the pharmaceutical is not a hazardous waste, it shall be managed in accordance with one of the following:
(1)Section 118215.
(2)Provisions relating to solid waste pursuant to Division 30 (commencing with Section 40000) of the Public Resources Code.
(b)This section shall remain in effect only until January 1, 2022, and as of that date is repealed, unless a later enacted statute, that is enacted before January 1, 2022, deletes or extends that date.
SEC. 4.(a)The Department of Toxic Substances Control shall convene a Retail Waste Working Group comprised of representatives of large retailers, small retailers, district attorneys, certified unified program agencies, nongovernment organizations, the State Department of Public Health, manufacturers, reverse distributors, and other stakeholders to do both of the following:
(1)Identify regulatory and policy directives that need clarification or specification when applied to consumer products.
(2)Adopt consensus recommendations to facilitate and increase sustainable practices and waste reduction opportunities for consumer products and to encourage safe and efficient options for managing the flow of surplus household consumer products through the reverse supply chain.
(b)By March 1, 2017, the Retail Waste Working Group shall identify a list of issues for discussion and resolution and, thereafter, shall meet regularly to assist and advise the Legislature, and shall report the consensus recommendations to the Legislature by June 1, 2017.
SEC. 5.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)Except as provided in subdivisions (b) and (c), (c) and Section 118216, a person generating or treating medical waste shall ensure that the medical waste is treated by one of the following methods, thereby rendering it solid waste, as defined in Section 40191 of the Public Resources Code, prior to before disposal:
(1)(A)Incineration at a permitted medical waste treatment facility in a controlled-air, multichamber incinerator, or other method of incineration approved by the department which that provides complete combustion of the waste into carbonized or mineralized ash.
(B)Treatment with an alternative technology approved pursuant to paragraph (3), which, due to the extremely high temperatures of treatment in excess of 1300 1,300 degrees Fahrenheit, has received express approval from the department.
(2)Steam sterilization at a permitted medical waste treatment facility or by other sterilization, in accordance with all of the following operating procedures for steam sterilizers or other sterilization:
(A)Standard written operating procedures shall be established for biological indicators, or for other indicators of adequate sterilization approved by the department, for each steam sterilizer, including time, temperature, pressure, type of waste, type of container, closure on container, pattern of loading, water content, and maximum load quantity.
(B)Recording or indicating thermometers shall be checked during each complete cycle to ensure the attainment of 121 Centigrade (250 121 degrees centigrade (250 degrees Fahrenheit) for at least one-half hour, depending on the quantity and density of the load, to achieve sterilization of the entire load. Thermometers, thermocouples, or other monitoring devices identified in the facility operating plan shall be checked for calibration annually. Records of the calibration checks shall be maintained as part of the facilitys files and records for a period of two years or for the period specified in the regulations.
(C)Heat-sensitive tape, or another method acceptable to the enforcement agency, shall be used on each biohazard bag or sharps container that is processed onsite to indicate that the waste went through heat treatment. If the biohazard bags or sharps containers are placed in a large liner bag within the autoclave for treatment, heat-sensitive tape or another method acceptable to the enforcement agency only needs to be placed on the liner bag and not on every hazardous waste bag or sharps container being treated.
(D)The biological indicator Geobacillus stearothermophilus, or other indicator of adequate sterilization as approved by the department, shall be placed at the center of a load processed under standard operating conditions at least monthly to confirm the attainment of adequate sterilization conditions.
(E)Records of the procedures specified in subparagraphs (A), (B), and (D) shall be maintained for a period of not less than two years.
(3)(A)Other alternative medical waste treatment methods which that are both of the following:
(i)Approved by the department.
(ii)Result in the destruction of pathogenic micro-organisms. microorganisms.
(B)Any alternative medical waste treatment method proposed to the department shall be evaluated by the department and either approved or rejected pursuant to the criteria specified in this subdivision.
(b)Fluid blood or fluid blood products may be discharged to a public sewage system without treatment if its discharge is consistent with waste discharge requirements placed on the public sewage system by the California regional water quality control board with jurisdiction.
(c)(1)A medical waste that is a biohazardous laboratory waste, as defined in subparagraph (B) of paragraph (1) of subdivision (b) of Section 117690, may be treated by a chemical disinfection if the waste is liquid or semiliquid and the chemical disinfection method is recognized by the National Institutes of Health, the Centers for Disease Control and Prevention, or the American Biological Safety Association, and if the use of chemical disinfection as a treatment method is identified in the sites medical waste management plan.
(2)If the waste is not treated by chemical disinfection, in accordance with paragraph (1), the waste shall be treated by one of the methods specified in subdivision (a).
(3)Following treatment by chemical disinfection, the medical waste may be discharged to the public sewage system if the discharge is consistent with waste discharge requirements placed on the public sewage system by the California regional water quality control board, and the discharge is in compliance with the requirements imposed by the owner or operator of the public sewage system. If the chemical disinfection of the medical waste causes the waste to become a hazardous waste, the waste shall be managed in accordance with the requirements of Chapter 6.5 (commencing with Section 25100) of Division 20.
(d)This section shall remain in effect only until January 1, 2022, and as of that date is repealed, unless a later enacted statute, that is enacted before January 1, 2022, deletes or extends that date.
SEC. 2.Section 118215 is added to the Health and Safety Code, to read:118215.(a)Except as provided in subdivisions (b) and (c), a person generating or treating medical waste shall ensure that the medical waste is treated by one of the following methods, thereby rendering it solid waste, as defined in Section 40191 of the Public Resources Code, before disposal:
(1)(A)Incineration at a permitted medical waste treatment facility in a controlled-air, multichamber incinerator, or other method of incineration approved by the department that provides complete combustion of the waste into carbonized or mineralized ash.
(B)Treatment with an alternative technology approved pursuant to paragraph (3), which, due to the extremely high temperatures of treatment in excess of 1,300 degrees Fahrenheit, has received express approval from the department.
(2)Steam sterilization at a permitted medical waste treatment facility or by other sterilization, in accordance with all of the following operating procedures for steam sterilizers or other sterilization:
(A)Standard written operating procedures shall be established for biological indicators, or for other indicators of adequate sterilization approved by the department, for each steam sterilizer, including time, temperature, pressure, type of waste, type of container, closure on container, pattern of loading, water content, and maximum load quantity.
(B)Recording or indicating thermometers shall be checked during each complete cycle to ensure the attainment of 121 degrees centigrade (250 degrees Fahrenheit) for at least one-half hour, depending on the quantity and density of the load, to achieve sterilization of the entire load. Thermometers, thermocouples, or other monitoring devices identified in the facility operating plan shall be checked for calibration annually. Records of the calibration checks shall be maintained as part of the facilitys files and records for a period of two years or for the period specified in the regulations.
(C)Heat-sensitive tape, or another method acceptable to the enforcement agency, shall be used on each biohazard bag or sharps container that is processed onsite to indicate that the waste went through heat treatment. If the biohazard bags or sharps containers are placed in a large liner bag within the autoclave for treatment, heat-sensitive tape or another method acceptable to the enforcement agency only needs to be placed on the liner bag and not on every hazardous waste bag or sharps container being treated.
(D)The biological indicator Geobacillus stearothermophilus, or other indicator of adequate sterilization as approved by the department, shall be placed at the center of a load processed under standard operating conditions at least monthly to confirm the attainment of adequate sterilization conditions.
(E)Records of the procedures specified in subparagraphs (A), (B), and (D) shall be maintained for a period of not less than two years.
(3)(A)Other alternative medical waste treatment methods that are both of the following:
(i)Approved by the department.
(ii)Result in the destruction of pathogenic microorganisms.
(B)Any alternative medical waste treatment method proposed to the department shall be evaluated by the department and either approved or rejected pursuant to the criteria specified in this subdivision.
(b)Fluid blood or fluid blood products may be discharged to a public sewage system without treatment if its discharge is consistent with waste discharge requirements placed on the public sewage system by the California regional water quality control board with jurisdiction.
(c)(1)A medical waste that is a biohazardous laboratory waste, as defined in subparagraph (B) of paragraph (1) of subdivision (b) of Section 117690, may be treated by a chemical disinfection if the waste is liquid or semiliquid and the chemical disinfection method is recognized by the National Institutes of Health, the Centers for Disease Control and Prevention, or the American Biological Safety Association, and if the use of chemical disinfection as a treatment method is identified in the sites medical waste management plan.
(2)If the waste is not treated by chemical disinfection, in accordance with paragraph (1), the waste shall be treated by one of the methods specified in subdivision (a).
(3)Following treatment by chemical disinfection, the medical waste may be discharged to the public sewage system if the discharge is consistent with waste discharge requirements placed on the public sewage system by the California regional water quality control board, and the discharge is in compliance with the requirements imposed by the owner or operator of the public sewage system. If the chemical disinfection of the medical waste causes the waste to become a hazardous waste, the waste shall be managed in accordance with the requirements of Chapter 6.5 (commencing with Section 25100) of Division 20.
(d)This section shall become operative on January 1, 2022.
SEC. 3.Section 118216 is added to the Health and Safety Code, to read:118216.(a)Notwithstanding Section 117690, a pharmaceutical that is offered for sale without a prescription shall, upon discard, be managed in accordance with Chapter 6.5 (commencing with Section 25100) of Division 20 if it is a hazardous waste as defined in Section 25117 and implementing regulations. If the pharmaceutical is not a hazardous waste, it shall be managed in accordance with one of the following:
(1)Section 118215.
(2)Provisions relating to solid waste pursuant to Division 30 (commencing with Section 40000) of the Public Resources Code.
(b)This section shall remain in effect only until January 1, 2022, and as of that date is repealed, unless a later enacted statute, that is enacted before January 1, 2022, deletes or extends that date.
SEC. 4.(a)The Department of Toxic Substances Control shall convene a Retail Waste Working Group comprised of representatives of large retailers, small retailers, district attorneys, certified unified program agencies, nongovernment organizations, the State Department of Public Health, manufacturers, reverse distributors, and other stakeholders to do both of the following:
(1)Identify regulatory and policy directives that need clarification or specification when applied to consumer products.
(2)Adopt consensus recommendations to facilitate and increase sustainable practices and waste reduction opportunities for consumer products and to encourage safe and efficient options for managing the flow of surplus household consumer products through the reverse supply chain.
(b)By March 1, 2017, the Retail Waste Working Group shall identify a list of issues for discussion and resolution and, thereafter, shall meet regularly to assist and advise the Legislature, and shall report the consensus recommendations to the Legislature by June 1, 2017.
SEC. 5.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
SECTION 1.Article 11.2 (commencing with Section 25230) is added to Chapter 6.5 of Division 20 of the Health and Safety Code, to read:11.2.Nonprescription Pharmaceutical Surplus Products25230.(a)The Legislature finds and declares that this section is intended to address the unique circumstances associated with the management of retail nonprescription pharmaceutical surplus products that potentially can be safely diverted from the waste stream for reuse, if appropriate. The Legislature further declares that this section shall not be construed to set a precedent applicable to the management, including disposal, of other hazardous or medical wastes.
(b)For purposes of this section, the following definitions shall apply:
(1)Retail nonprescription pharmaceutical surplus product means a pharmaceutical, as that term is defined in Section 117747, that may be sold without a prescription and that is labeled for use by the consumer in accordance with the requirements of the laws and rules of this state and the federal government, defined as a nonprescription drug in Article 2 (commencing with Section 4015) of Chapter 9 of Division 2 of the Business and Professions Code, in which a waste generator has made a reasonable determination for reuse. A retail nonprescription pharmaceutical surplus product does not include waste that is subject to regulation as a hazardous waste under the federal Resource Conservation and Recovery Act of 1976, as amended (42 U.S.C. Sec. 6901 et seq.).
(2)Reasonable determination for reuse means, upon removal of a retail nonprescription pharmaceutical surplus product from sale, a generator who has evaluated the product and makes a finding that the product meets all of the following criteria:
(A)The product is in unadulterated packaging.
(B)The product and packaging are in a condition that is suitable for resale.
(C)The product is not designated for disposal by the manufacturer or the manufacturers agent.
(D)The product is otherwise eligible for liquidation or donation.
(3)Reverse distributor or reverse distribution center has the same meaning as set forth in Section 4040.5 of the Business and Professions Code that satisfies all of the following:
(A)Is licensed as a wholesaler of dangerous drugs by the California State Board of Pharmacy pursuant to Section 4160 of the Business and Professions Code.
(B)Is permitted by the State Department of Public Health as a transfer station, if the reverse distributor is located within the State of California.
(C)Is registered with the Department of Toxic Substances Control and any other appropriate state and local agencies as a hazardous waste generator, transfer facility, or storage facility.
(D)Complies with handling, storage, training, emergency response, and recordkeeping requirements, and any other applicable requirements.
(c)Notwithstanding Sections 25189.5, 25201, and 117747, if a reasonable determination for reuse has been made, a retail nonprescription pharmaceutical surplus product may be handled in accordance with all of the following:
(1)The retail nonprescription pharmaceutical surplus product shall be transported to a reverse distributor or reverse distribution center for any of the following purposes:
(A)Evaluating the manufacturers or suppliers credit or other financial reconciliation.
(B)Liquidation.
(C)Donation.
(D)Transferring back to a manufacturer, distributor, or supplier, or its respective agent.
(2)The retail nonprescription pharmaceutical surplus product shall be transported with a tracking document that identifies all of the following information:
(A)The product, the UPC label, and the lot number.
(B)Name, address, and telephone number of the generator of the waste.
(C)Name, address, and telephone number of the reverse distributor or reverse distribution center receiving the shipment.
(D)The purpose for which the retail nonprescription pharmaceutical surplus product is being shipped to the reverse distributor or reverse distribution center.
(3)Shipments of retail nonprescription pharmaceutical surplus products to a reverse distributor or a reverse distribution center shall be made via a transporter registered with the United States Department of Transportation Federal Motor Carrier Safety Administration. Transporters shall use due diligence to ensure safe handling, which includes, but is not limited to, ensuring that the packaging does not become damaged or adulterated during shipment and that the shipment is handled in appropriate moisture and temperature conditions.
(4)The reverse distributor or reverse distribution center shall do all of the following:
(A)Maintain the specified tracking documents for a period of three years following receipt date of a shipment and shall make those documents available for inspection by any applicable enforcement agencies.
(B)Submit a hazardous materials business plan to the appropriate state and local agencies, as required by Article 1 (commencing with Section 25500) of Chapter 6.95 and any regulations promulgated by either the Department of Toxic Substances Control or any certified unified program agency.
(d)A retail nonprescription pharmaceutical surplus product that has been transported to a reverse distributor or reverse distribution center for any of the purposes listed in paragraph (1) of subdivision (c) shall not be stored or held at the reverse distributor or reverse distribution center for more than 364 calendar days. A retail nonprescription pharmaceutical surplus product held or stored for 365 or more days shall immediately be considered waste and, if hazardous, managed in accordance with applicable federal and state hazardous waste management laws and regulations.
(e)Notwithstanding Sections 25189.5, 25201, and 117747, the provisions of subdivision (c) may be used for a retail nonprescription pharmaceutical surplus product for which a reasonable determination for reuse cannot be made if the product has been recalled as required by law, including safety recalls for secure destruction.
(f)The State Department of Public Health may adopt regulations as deemed necessary to establish standards for the proper and safe handling of retail nonprescription pharmaceutical surplus products.
(g)A facility that elects to manage its retail nonprescription pharmaceutical surplus products pursuant to this article is not subject to regulation of those products under either the Medical Waste Management Act (Part 14 (commencing with Section 117600) of Division 104) or any other provision of this chapter.
(h)This article shall remain in effect only until January 1, 2022, and as of that date is repealed, unless a later enacted statute, that is enacted before January 1, 2022, deletes or extends that date.
SEC. 2.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
SEC. 3.This act is an urgency statute necessary for the immediate preservation of the public peace, health, or safety within the meaning of Article IV of the Constitution and shall go into immediate effect. The facts constituting the necessity are:
In order to make statutory changes needed to address the unique circumstances associated with the management, handling, and reasonable determination of reuse or retail nonprescription pharmaceutical surplus products as soon as possible, it is necessary that this act take effect immediately.
(a)The Legislature finds and declares that this section is intended to address the unique circumstances associated with the management of retail nonprescription pharmaceutical surplus products that potentially can be safely diverted from the waste stream for reuse, if appropriate. The Legislature further declares that this section shall not be construed to set a precedent applicable to the management, including disposal, of other hazardous or medical wastes.
(b)For purposes of this section, the following definitions shall apply:
(1)Retail nonprescription pharmaceutical surplus product means a pharmaceutical, as that term is defined in Section 117747, that may be sold without a prescription and that is labeled for use by the consumer in accordance with the requirements of the laws and rules of this state and the federal government, defined as a nonprescription drug in Article 2 (commencing with Section 4015) of Chapter 9 of Division 2 of the Business and Professions Code, in which a waste generator has made a reasonable determination for reuse. A retail nonprescription pharmaceutical surplus product does not include waste that is subject to regulation as a hazardous waste under the federal Resource Conservation and Recovery Act of 1976, as amended (42 U.S.C. Sec. 6901 et seq.).
(2)Reasonable determination for reuse means, upon removal of a retail nonprescription pharmaceutical surplus product from sale, a generator who has evaluated the product and makes a finding that the product meets all of the following criteria:
(A)The product is in unadulterated packaging.
(B)The product and packaging are in a condition that is suitable for resale.
(C)The product is not designated for disposal by the manufacturer or the manufacturers agent.
(D)The product is otherwise eligible for liquidation or donation.
(3)Reverse distributor or reverse distribution center has the same meaning as set forth in Section 4040.5 of the Business and Professions Code that satisfies all of the following:
(A)Is licensed as a wholesaler of dangerous drugs by the California State Board of Pharmacy pursuant to Section 4160 of the Business and Professions Code.
(B)Is permitted by the department State Department of Public Health as a transfer station, if the reverse distributor is located within the State of California.
(C)Is registered with the Department of Toxic Substances Control and any other appropriate state and local agencies as a hazardous waste generator, transfer facility, or storage facility.
(D)Complies with handling, storage, training, emergency response, and recordkeeping requirements, and any other applicable requirements.
(c)Notwithstanding Sections 25189.5, 25201, and 117747, if a reasonable determination for reuse has been made, a retail nonprescription pharmaceutical surplus product may be handled in accordance with all of the following:
(1)The retail nonprescription pharmaceutical surplus product shall be transported to a reverse distributor or reverse distribution center for any of the following purposes:
(A)Evaluating the manufacturers or suppliers credit or other financial reconciliation.
(B)Liquidation.
(C)Donation.
(D)Transferring back to a manufacturer, distributor, or supplier, or its respective agent.
(2)The retail nonprescription pharmaceutical surplus product shall be transported with a tracking document that identifies all of the following information:
(A)The product, the UPC label, and the lot number.
(B)Name, address, and telephone number of the generator of the waste.
(C)Name, address, and telephone number of the reverse distributor or reverse distribution center receiving the shipment.
(D)The purpose for which the retail nonprescription pharmaceutical surplus product is being shipped to the reverse distributor or reverse distribution center.
(3)Shipments of retail nonprescription pharmaceutical surplus products to a reverse distributor or a reverse distribution center shall be made via a transporter registered with the United States Department of Transportation Federal Motor Carrier Safety Administration. Transporters shall use due diligence to ensure safe handling, which includes, but is not limited to, ensuring that the packaging does not become damaged or adulterated during shipment and that the shipment is handled in appropriate moisture and temperature conditions.
(4)The reverse distributor or reverse distribution center shall do all of the following:
(A)Maintain the specified tracking documents for a period of three years following receipt date of a shipment and shall make those documents available for inspection by any applicable enforcement agencies.
(B)Submit a hazardous materials business plan to the appropriate state and local agencies, as required by Article 1 (commencing with Section 25500) of Chapter 6.95 and any regulations promulgated by either the department Department of Toxic Substances Control or any certified unified program agency.
(d)A retail nonprescription pharmaceutical surplus product that has been transported to a reverse distributor or reverse distribution center for any of the purposes listed in paragraph (1) of subdivision (c) shall not be stored or held at the reverse distributor or reverse distribution center for more than 364 calendar days. A retail nonprescription pharmaceutical surplus product held or stored for 365 or more days shall immediately be considered waste and, if hazardous, managed in accordance with applicable federal and state hazardous waste management laws and regulations.
(e)Notwithstanding Sections 25189.5, 25201, and 117747, the provisions of subdivision (c) may be used for a retail nonprescription pharmaceutical surplus product for which a reasonable determination for reuse cannot be made if the product has been recalled as required by law, including safety recalls for secure destruction.
(f)The department State Department of Public Health may adopt regulations as deemed necessary to establish standards for the proper and safe handling of retail nonprescription pharmaceutical surplus products.
(g)A facility that elects to manage its retail nonprescription pharmaceutical surplus products pursuant to this article is not subject to regulation of those products under either the Medical Waste Management Act (Part 14 (commencing with Section 117600) of Division 104) or any other provision of this chapter.
(g)
(h)This article shall remain in effect only until January 1, 2022, and as of that date is repealed, unless a later enacted statute, that is enacted before January 1, 2022, deletes or extends that date.
SEC. 2.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
SEC. 3.This act is an urgency statute necessary for the immediate preservation of the public peace, health, or safety within the meaning of Article IV of the Constitution and shall go into immediate effect. The facts constituting the necessity are:
In order to make statutory changes needed to address the unique circumstances associated with the management, handling, and reasonable determination of reuse or retail nonprescription pharmaceutical surplus products as soon as possible, it is necessary that this act take effect immediately.
(a)The Legislature finds and declares that this section is intended to address the unique circumstances associated with the management of retail nonprescription pharmaceutical surplus products that potentially can be safely diverted from the waste stream for reuse, if appropriate. The Legislature further declares that this section shall not be construed to set a precedent applicable to the management, including disposal, of other hazardous or medical wastes.
(b)For purposes of this section, the following definitions shall apply:
(1)Retail nonprescription pharmaceutical surplus product means a pharmaceutical, as that term is defined in Section 117747, that may be sold without a prescription and that is labeled for use by the consumer in accordance with the requirements of the laws and rules of this state and the federal government, defined as a nonprescription drug in Article 2 (commencing with Section 4015) of Chapter 9 of Division 2 of the Business and Professions Code, in which a waste generator has made a reasonable determination for reuse. A retail nonprescription pharmaceutical surplus product does not include waste that is subject to regulation as a hazardous waste under the federal Resource Conservation and Recovery Act of 1976, as amended (42 U.S.C. Sec. 6901 et seq.).
(2)Reasonable determination for reuse means, upon removal of a retail nonprescription pharmaceutical surplus product from sale, a generator who has evaluated the product and makes a finding that the product meets all of the following criteria:
(A)The product is in unadulterated packaging.
(B)The product and packaging are in a condition that is suitable for resale.
(C)The product is not designated for disposal by the manufacturer or the manufacturers agent.
(D)The product is otherwise eligible for liquidation or donation.
(3)Reverse distributor or reverse distribution center has the same meaning as set forth in Section 4040.5 of the Business and Professions Code that satisfies all of the following:
(A)Is licensed as a wholesaler of dangerous drugs by the California State Board of Pharmacy pursuant to Section 4160 of the Business and Professions Code.
(B)Is permitted by the department as a transfer station, if the reverse distributor is located within the State of California.
(C)Is registered with the Department of Toxic Substances Control and any other appropriate state and local agencies as a hazardous waste generator, transfer facility, or storage facility.
(D)Complies with handling, storage, training, emergency response, and recordkeeping requirements, and any other applicable requirements.
(c)Notwithstanding Sections 25189.5, 25201, and 117747, if a reasonable determination for reuse has been made, a retail nonprescription pharmaceutical surplus product may be handled in accordance with all of the following:
(1)The retail nonprescription pharmaceutical surplus product shall be transported to a reverse distributor or reverse distribution center for any of the following purposes:
(A)Evaluating the manufacturers or suppliers credit or other financial reconciliation.
(B)Liquidation.
(C)Donation.
(D)Transferring back to a manufacturer, distributor, or supplier, or its respective agent.
(2)The retail nonprescription pharmaceutical surplus product shall be transported with a tracking document that identifies all of the following information:
(A)The product, the UPC label, and the lot number.
(B)Name, address, and telephone number of the generator of the waste.
(C)Name, address, and telephone number of the reverse distributor or reverse distribution center receiving the shipment.
(D)The purpose for which the retail nonprescription pharmaceutical surplus product is being shipped to the reverse distributor or reverse distribution center.
(3)Shipments of retail nonprescription pharmaceutical surplus products to a reverse distributor or a reverse distribution center shall be made via a transporter registered with the United States Department of Transportation Federal Motor Carrier Safety Administration. Transporters shall use due diligence to ensure safe handling, which includes, but is not limited to, ensuring that the packaging does not become damaged or adulterated during shipment and that the shipment is handled in appropriate moisture and temperature conditions.
(4)The reverse distributor or reverse distribution center shall do all of the following:
(A)Maintain the specified tracking documents for a period of three years following receipt date of a shipment and shall make those documents available for inspection by any applicable enforcement agencies.
(B)Submit a hazardous materials business plan to the appropriate state and local agencies, as required by Article 1 (commencing with Section 25500) of Chapter 6.95 and any regulations promulgated by either the department or any certified unified program agency.
(d)A retail nonprescription pharmaceutical surplus product that has been transported to a reverse distributor or reverse distribution center for any of the purposes listed in paragraph (1) of subdivision (c) shall not be stored or held at the reverse distributor or reverse distribution center for more than 364 calendar days. A retail nonprescription pharmaceutical surplus product held or stored for 365 or more days shall immediately be considered waste and, if hazardous, managed in accordance with applicable federal and state hazardous waste management laws and regulations.
(e)Notwithstanding Sections 25189.5, 25201, and 117747, the provisions of subdivision (c) may be used for a retail nonprescription pharmaceutical surplus product for which a reasonable determination for reuse cannot be made if the product has been recalled as required by law, including safety recalls for secure destruction.
(f)The department may adopt regulations as deemed necessary to establish standards for the proper and safe handling of retail nonprescription pharmaceutical surplus products.
(g)This article shall remain in effect only until January 1, 2022, and as of that date is repealed, unless a later enacted statute, that is enacted before January 1, 2022, deletes or extends that date.
SEC. 2.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
SEC. 3.This act is an urgency statute necessary for the immediate preservation of the public peace, health, or safety within the meaning of Article IV of the Constitution and shall go into immediate effect. The facts constituting the necessity are:
In order to make statutory changes needed to address the unique circumstances associated with the management, handling, and reasonable determination of reuse or retail nonprescription pharmaceutical surplus products as soon as possible, it is necessary that this act take effect immediately.
SECTION 1.Section 117690 of the Health and Safety Code is amended to read:117690.(a)Medical waste means any biohazardous, pathology, pharmaceutical, or trace chemotherapy waste not regulated by the federal Resource Conservation and Recovery Act of 1976 (Public Law 94-580), as amended; sharps and trace chemotherapy wastes generated in a health care setting in the diagnosis, treatment, immunization, or care of humans or animals; waste generated in autopsy or necropsy; waste generated during preparation of a body for final disposition such as cremation or interment; waste generated in research pertaining to the production or testing of microbiologicals; waste generated in research using human or animal pathogens; sharps and laboratory waste that poses a potential risk of infection to humans generated in the inoculation of animals in commercial farming operations; waste generated from the consolidation of home-generated sharps; and waste generated in the cleanup of trauma scenes. Biohazardous, pathology, pharmaceutical, sharps, and trace chemotherapy wastes that meet the conditions of this section are not subject to any of the hazardous waste requirements found in Chapter 6.5 (commencing with Section 25100) of Division 20.
(b)For purposes of this part the following definitions apply:
(1)Biohazardous waste includes all of the following:
(A)(i)Regulated medical waste, clinical waste, or biomedical waste that is a waste or reusable material derived from the medical treatment of a human or from an animal that is suspected by the attending veterinarian of being infected with a pathogen that is also infectious to humans, which includes diagnosis and immunization; or from biomedical research, which includes the production and testing of biological products.
(ii)Regulated medical waste or clinical waste or biomedical waste suspected of containing a highly communicable disease.
(B)Laboratory waste such as human specimen cultures or animal specimen cultures that are infected with pathogens that are also infectious to humans; cultures and stocks of infectious agents from research; wastes from the production of bacteria, viruses, spores, discarded live and attenuated vaccines used in human health care or research, discarded animal vaccines, including Brucellosis and Contagious Ecthyma, as defined by the department; culture dishes, devices used to transfer, inoculate, and mix cultures; and wastes identified by Section 173.134 of Title 49 of the Code of Federal Regulations as Category B once wasted for laboratory wastes.
(C)Waste that, at the point of transport from the generators site or at the point of disposal contains recognizable fluid human blood, fluid human blood products, containers, or equipment containing human blood that is fluid, or blood from animals suspected by the attending veterinarian of being contaminated with infectious agents known to be contagious to humans.
(D)Waste containing discarded materials contaminated with excretion, exudate, or secretions from humans or animals that are required to be isolated by the infection control staff, the attending physician and surgeon, the attending veterinarian, or the local health officer, to protect others from highly communicable diseases or diseases of animals that are communicable to humans.
(2)Pathology waste includes both of the following:
(A)Human body parts, with the exception of teeth, removed at surgery and surgery specimens or tissues removed at surgery or autopsy that are suspected by the health care professional of being contaminated with infectious agents known to be contagious to humans or having been fixed in formaldehyde or another fixative.
(B)Animal parts, tissues, fluids, or carcasses suspected by the attending veterinarian of being contaminated with infectious agents known to be contagious to humans.
(3)Pharmaceutical waste means a pharmaceutical, as defined in Section 117747, including trace chemotherapy waste, that is a waste, as defined in Section 25124. For purposes of this part, pharmaceutical waste does not include a pharmaceutical that meets any of the following criteria:
(A)The pharmaceutical is being sent out of the state to a reverse distributor, as defined in Section 4040.5 of the Business and Professions Code, that is licensed as a wholesaler of dangerous drugs by the California State Board of Pharmacy pursuant to Section 4161 of the Business and Professions Code.
(B)The pharmaceutical is being sent by a reverse distributor, as defined in Section 4040.5 of the Business and Professions Code, offsite for treatment and disposal in accordance with applicable laws, or to a reverse distributor that is licensed as a wholesaler of dangerous drugs by the California State Board of Pharmacy pursuant to Section 4160 of the Business and Professions Code and as a permitted transfer station if the reverse distributor is located within the state.
(C)The pharmaceutical is an over-the-counter human or veterinary drug or dietary supplement that meets all of the following requirements:
(i)Is offered for sale without a prescription.
(ii)Is labeled with information entitled Drug Facts or Supplement Facts, in accordance with the requirements of the Federal Food, Drug, and Cosmetic Act, as amended, (21 U.S.C.A. Sec. 321 et seq.).
(iii)Is characterized and managed as either a hazardous waste pursuant to Chapter 6.5 (commencing with Section 25100) of Division 20, or a solid waste pursuant to Division 30 (commencing with Section 40000) of the Public Resources Code.
(iv)With respect to an over-the-counter human or veterinary drug, is not disposed of on land within the state.
(4)Sharps waste means a device that has acute rigid corners, edges, or protuberances capable of cutting or piercing, including, but not limited to, hypodermic needles, hypodermic needles with syringes, blades, needles with attached tubing, acupuncture needles, root canal files, broken glass items used in health care such as Pasteur pipettes and blood vials contaminated with biohazardous waste, and any item capable of cutting or piercing from trauma scene waste.
(5)Trace chemotherapeutic waste means waste that is contaminated through contact with, or having previously contained, chemotherapeutic agents, including, but not limited to, gloves, disposable gowns, towels, and intravenous solution bags and attached tubing that are empty. A biohazardous waste that meets the conditions of this paragraph is not subject to the hazardous waste requirements of Chapter 6.5 (commencing with Section 25100) of Division 20.
(6)Trauma scene waste means waste that is a regulated waste, as defined in Section 5193 of Title 8 of the California Code of Regulations, and that has been removed, is to be removed, or is in the process of being removed, from a trauma scene by a trauma scene waste management practitioner.
SEC. 2.This act is an urgency statute necessary for the immediate preservation of the public peace, health, or safety within the meaning of Article IV of the Constitution and shall go into immediate effect. The facts constituting the necessity are:
In order to make statutory changes needed to exempt over-the-counter human or veterinary drugs or dietary supplements from laws regulating the management, handling, and disposal of medical waste, as soon as possible, it is necessary that this act take effect immediately.
(a)Medical waste means any biohazardous, pathology, pharmaceutical, or trace chemotherapy waste not regulated by the federal Resource Conservation and Recovery Act of 1976 (Public Law 94-580), as amended; sharps and trace chemotherapy wastes generated in a health care setting in the diagnosis, treatment, immunization, or care of humans or animals; waste generated in autopsy or necropsy; waste generated during preparation of a body for final disposition such as cremation or interment; waste generated in research pertaining to the production or testing of microbiologicals; waste generated in research using human or animal pathogens; sharps and laboratory waste that poses a potential risk of infection to humans generated in the inoculation of animals in commercial farming operations; waste generated from the consolidation of home-generated sharps; and waste generated in the cleanup of trauma scenes. Biohazardous, pathology, pharmaceutical, sharps, and trace chemotherapy wastes that meet the conditions of this section are not subject to any of the hazardous waste requirements found in Chapter 6.5 (commencing with Section 25100) of Division 20.
(b)For purposes of this part the following definitions apply:
(1)Biohazardous waste includes all of the following:
(A)(i)Regulated medical waste, clinical waste, or biomedical waste that is a waste or reusable material derived from the medical treatment of a human or from an animal that is suspected by the attending veterinarian of being infected with a pathogen that is also infectious to humans, which includes diagnosis and immunization; or from biomedical research, which includes the production and testing of biological products.
(ii)Regulated medical waste or clinical waste or biomedical waste suspected of containing a highly communicable disease.
(B)Laboratory waste such as human specimen cultures or animal specimen cultures that are infected with pathogens that are also infectious to humans; cultures and stocks of infectious agents from research; wastes from the production of bacteria, viruses, spores, discarded live and attenuated vaccines used in human health care or research, discarded animal vaccines, including Brucellosis and Contagious Ecthyma, as defined by the department; culture dishes, devices used to transfer, inoculate, and mix cultures; and wastes identified by Section 173.134 of Title 49 of the Code of Federal Regulations as Category B once wasted for laboratory wastes.
(C)Waste that, at the point of transport from the generators site or at the point of disposal contains recognizable fluid human blood, fluid human blood products, containers, or equipment containing human blood that is fluid, or blood from animals suspected by the attending veterinarian of being contaminated with infectious agents known to be contagious to humans.
(D)Waste containing discarded materials contaminated with excretion, exudate, or secretions from humans or animals that are required to be isolated by the infection control staff, the attending physician and surgeon, the attending veterinarian, or the local health officer, to protect others from highly communicable diseases or diseases of animals that are communicable to humans.
(2)Pathology waste includes both of the following:
(A)Human body parts, with the exception of teeth, removed at surgery and surgery specimens or tissues removed at surgery or autopsy that are suspected by the health care professional of being contaminated with infectious agents known to be contagious to humans or having been fixed in formaldehyde or another fixative.
(B)Animal parts, tissues, fluids, or carcasses suspected by the attending veterinarian of being contaminated with infectious agents known to be contagious to humans.
(3)Pharmaceutical waste means a pharmaceutical, as defined in Section 117747, including trace chemotherapy waste, that is a waste, as defined in Section 25124. For purposes of this part, pharmaceutical waste does not include a pharmaceutical that meets any of the following criteria:
(A)The pharmaceutical is being sent out of the state to a reverse distributor, as defined in Section 4040.5 of the Business and Professions Code, that is licensed as a wholesaler of dangerous drugs by the California State Board of Pharmacy pursuant to Section 4161 of the Business and Professions Code.
(B)The pharmaceutical is being sent by a reverse distributor, as defined in Section 4040.5 of the Business and Professions Code, offsite for treatment and disposal in accordance with applicable laws, or to a reverse distributor that is licensed as a wholesaler of dangerous drugs by the California State Board of Pharmacy pursuant to Section 4160 of the Business and Professions Code and as a permitted transfer station if the reverse distributor is located within the state.
(C)The pharmaceutical is an over-the-counter human or veterinary drug or dietary supplement that meets all of the following requirements:
(i)Is offered for sale without a prescription.
(ii)Is labeled with information entitled Drug Facts or Supplement Facts, in accordance with the requirements of the Federal Food, Drug, and Cosmetic Act, as amended, (21 U.S.C.A. Sec. 321 et seq.).
(iii)Is characterized and managed as either a hazardous waste pursuant to Chapter 6.5 (commencing with Section 25100) of Division 20, or a solid waste pursuant to Division 30 (commencing with Section 40000) of the Public Resources Code.
(iv)With respect to an over-the-counter human or veterinary drug, is not disposed of on land within the state.
(4)Sharps waste means a device that has acute rigid corners, edges, or protuberances capable of cutting or piercing, including, but not limited to, hypodermic needles, hypodermic needles with syringes, blades, needles with attached tubing, acupuncture needles, root canal files, broken glass items used in health care such as Pasteur pipettes and blood vials contaminated with biohazardous waste, and any item capable of cutting or piercing from trauma scene waste.
(5)Trace chemotherapeutic waste means waste that is contaminated through contact with, or having previously contained, chemotherapeutic agents, including, but not limited to, gloves, disposable gowns, towels, and intravenous solution bags and attached tubing that are empty. A biohazardous waste that meets the conditions of this paragraph is not subject to the hazardous waste requirements of Chapter 6.5 (commencing with Section 25100) of Division 20.
(6)Trauma scene waste means waste that is a regulated waste, as defined in Section 5193 of Title 8 of the California Code of Regulations, and that has been removed, is to be removed, or is in the process of being removed, from a trauma scene by a trauma scene waste management practitioner.
SEC. 2.This act is an urgency statute necessary for the immediate preservation of the public peace, health, or safety within the meaning of Article IV of the Constitution and shall go into immediate effect. The facts constituting the necessity are:
In order to make statutory changes needed to exempt over-the-counter human or veterinary drugs or dietary supplements from laws regulating the management, handling, and disposal of medical waste, as soon as possible, it is necessary that this act take effect immediately.
(a)Medical waste means any biohazardous, pathology, pharmaceutical, or trace chemotherapy waste not regulated by the federal Resource Conservation and Recovery Act of 1976 (Public Law 94-580), as amended; sharps and trace chemotherapy wastes generated in a health care setting in the diagnosis, treatment, immunization, or care of humans or animals; waste generated in autopsy or necropsy; waste generated during preparation of a body for final disposition such as cremation or interment; waste generated in research pertaining to the production or testing of microbiologicals; waste generated in research using human or animal pathogens; sharps and laboratory waste that poses a potential risk of infection to humans generated in the inoculation of animals in commercial farming operations; waste generated from the consolidation of home-generated sharps; and waste generated in the cleanup of trauma scenes. Biohazardous, pathology, pharmaceutical, sharps, and trace chemotherapy wastes that meet the conditions of this section are not subject to any of the hazardous waste requirements found in Chapter 6.5 (commencing with Section 25100) of Division 20.
(b)For purposes of this part the following definitions apply:
(1)Biohazardous waste includes all of the following:
(A)(i)Regulated medical waste, clinical waste, or biomedical waste that is a waste or reusable material derived from the medical treatment of a human or from an animal that is suspected by the attending veterinarian of being infected with a pathogen that is also infectious to humans, which includes diagnosis and immunization; or from biomedical research, which includes the production and testing of biological products.
(ii)Regulated medical waste or clinical waste or biomedical waste suspected of containing a highly communicable disease.
(B)Laboratory waste such as human specimen cultures or animal specimen cultures that are infected with pathogens that are also infectious to humans; cultures and stocks of infectious agents from research; wastes from the production of bacteria, viruses, spores, discarded live and attenuated vaccines used in human health care or research, discarded animal vaccines, including Brucellosis and Contagious Ecthyma, as defined by the department; culture dishes, devices used to transfer, inoculate, and mix cultures; and wastes identified by Section 173.134 of Title 49 of the Code of Federal Regulations as Category B once wasted for laboratory wastes.
(C)Waste that, at the point of transport from the generators site or at the point of disposal contains recognizable fluid human blood, fluid human blood products, containers, or equipment containing human blood that is fluid, or blood from animals suspected by the attending veterinarian of being contaminated with infectious agents known to be contagious to humans.
(D)Waste containing discarded materials contaminated with excretion, exudate, or secretions from humans or animals that are required to be isolated by the infection control staff, the attending physician and surgeon, the attending veterinarian, or the local health officer, to protect others from highly communicable diseases or diseases of animals that are communicable to humans.
(2)Pathology waste includes both of the following:
(A)Human body parts, with the exception of teeth, removed at surgery and surgery specimens or tissues removed at surgery or autopsy that are suspected by the health care professional of being contaminated with infectious agents known to be contagious to humans or having been fixed in formaldehyde or another fixative.
(B)Animal parts, tissues, fluids, or carcasses suspected by the attending veterinarian of being contaminated with infectious agents known to be contagious to humans.
(3)Pharmaceutical waste means a pharmaceutical, as defined in Section 117747, including trace chemotherapy waste, that is a waste, as defined in Section 25124. For purposes of this part, pharmaceutical waste does not include a pharmaceutical that meets either any of the following criteria:
(A)The pharmaceutical is being sent out of the state to a reverse distributor, as defined in Section 4040.5 of the Business and Professions Code, that is licensed as a wholesaler of dangerous drugs by the California State Board of Pharmacy pursuant to Section 4161 of the Business and Professions Code.
(B)The pharmaceutical is being sent by a reverse distributor, as defined in Section 4040.5 of the Business and Professions Code, offsite for treatment and disposal in accordance with applicable laws, or to a reverse distributor that is licensed as a wholesaler of dangerous drugs by the California State Board of Pharmacy pursuant to Section 4160 of the Business and Professions Code and as a permitted transfer station if the reverse distributor is located within the state.
(C)The pharmaceutical is an over-the-counter human or veterinary drug or dietary supplement that meets all of the following requirements:
(i)Is offered for sale without a prescription.
(ii)Is labeled with information entitled Drug Facts or Supplement Facts, in accordance with the requirements of the Federal Food, Drug, and Cosmetic Act, as amended, (21 U.S.C.A. Sec. 321 et seq.).
(iii)Is characterized and managed as either a hazardous waste pursuant to Chapter 6.5 (commencing with Section 25100) of Division 20, or a solid waste pursuant to Division 30 (commencing with Section 40000) of the Public Resources Code.
(iv)With respect to an over-the-counter human or veterinary drug, is not disposed of on land within the state.
(4)Sharps waste means a device that has acute rigid corners, edges, or protuberances capable of cutting or piercing, including, but not limited to, hypodermic needles, hypodermic needles with syringes, blades, needles with attached tubing, acupuncture needles, root canal files, broken glass items used in health care such as Pasteur pipettes and blood vials contaminated with biohazardous waste, and any item capable of cutting or piercing from trauma scene waste.
(5)Trace chemotherapeutic waste means waste that is contaminated through contact with, or having previously contained, chemotherapeutic agents, including, but not limited to, gloves, disposable gowns, towels, and intravenous solution bags and attached tubing that are empty. A biohazardous waste that meets the conditions of this paragraph is not subject to the hazardous waste requirements of Chapter 6.5 (commencing with Section 25100) of Division 20.
(6)Trauma scene waste means waste that is a regulated waste, as defined in Section 5193 of Title 8 of the California Code of Regulations, and that has been removed, is to be removed, or is in the process of being removed, from a trauma scene by a trauma scene waste management practitioner.
|
Date
|
Status
|
|---|---|
| Aug 15, 2016 | Read second time and amended. Ordered to second reading. |
| Sep 1, 2015 | Read third time. Urgency clause adopted. Passed. (Ayes 40. Noes 0. Page 2364.) Ordered to the Assembly. |
| Sep 1, 2015 | Read third time. Urgency clause adopted. Passed. (Ayes 40. Noes 0.) Ordered to the Assembly. |
| Jun 13, 2016 | Referred to Com. on E.S. & T.M. |
| Jun 21, 2016 | From committee with author's amendments. Read second time and amended. Re-referred to Com. on E.S. & T.M. |
| Jun 29, 2016 | From committee: Do pass as amended and re-refer to Com. on APPR. (Ayes 7. Noes 0.) (June 28). |
| Jun 30, 2016 | Read second time and amended. Re-referred to Com. on APPR. |
| Aug 1, 2016 | From committee with author's amendments. Read second time and amended. Re-referred to Com. on APPR. |
| Aug 3, 2016 | August 3 set for first hearing. Placed on APPR. suspense file. |
| Aug 12, 2016 | From committee: Do pass as amended. (Ayes 15. Noes 0.) (August 11). |
| Sep 1, 2015 | In Assembly. Read first time. Held at Desk. |
| Aug 16, 2016 | Read second time. Ordered to third reading. |
| Aug 18, 2016 | Read third time. Passed. Ordered to the Senate. |
| Aug 18, 2016 | Read third time. Passed. (Ayes 77. Noes 1. Page 5916.) Ordered to the Senate. |
| Aug 19, 2016 | In Senate. Concurrence in Assembly amendments pending. |
| Aug 23, 2016 | Ordered to special consent calendar. |
| Aug 25, 2016 | Assembly amendments concurred in. (Ayes 39. Noes 0. Page 5428.) Ordered to engrossing and enrolling. |
| Aug 25, 2016 | Assembly amendments concurred in. (Ayes 39. Noes 0.) Ordered to engrossing and enrolling. |
| Aug 30, 2016 | Enrolled and presented to the Governor at 1:30 p.m. |
| Jul 6, 2015 | From committee with author's amendments. Read second time and amended. Re-referred to Com. on E.Q. |
| Feb 26, 2015 | From printer. May be acted upon on or after March 28. |
| Mar 5, 2015 | Referred to Com. on E.Q. |
| Mar 17, 2015 | Set for hearing April 15. |
| Mar 26, 2015 | April 15 set for first hearing canceled at the request of author. |
| Jun 3, 2015 | From committee with author's amendments. Read second time and amended. Re-referred to Com. on E.Q. |
| Jun 5, 2015 | Set for hearing June 17. |
| Jun 10, 2015 | June 17 hearing postponed by committee. |
| Jun 25, 2015 | Set for hearing July 15. |
| Feb 25, 2015 | Introduced. Read first time. To Com. on RLS. for assignment. To print. |
| Jul 16, 2015 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 7. Noes 0. Page 2012.) (July 15). Re-referred to Com. on APPR. |
| Jul 16, 2015 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 7. Noes 0.) (July 15). Re-referred to Com. on APPR. |
| Jul 23, 2015 | Set for hearing August 17. |
| Aug 17, 2015 | August 17 hearing: Placed on APPR. suspense file. |
| Aug 21, 2015 | Set for hearing August 27. |
| Aug 27, 2015 | From committee: Do pass as amended. (Ayes 7. Noes 0. Page 2216.) (August 27). |
| Aug 27, 2015 | From committee: Do pass as amended. (Ayes 7. Noes 0.) (August 27). |
| Aug 31, 2015 | Read second time and amended. Ordered to third reading. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Aug 25, 2016 | Special Consent SB423 Bates | Senate Floor |
Passed |
|
| Aug 18, 2016 | SB 423 Bates Senate Third Reading By ALEJO | Assembly Floor |
Passed |
|
| Aug 11, 2016 | Do pass as amended. | Assembly Standing Committee on Appropriations |
Passed |
|
| Jun 28, 2016 | Do pass as amended and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Environmental Safety and Toxic Materials |
Passed |
|
| Sep 1, 2015 | Senate 3rd Reading SB423 Bates Urgency Clause | Senate Floor |
Passed |
|
| Aug 27, 2015 | Do pass as amended | Senate Standing Committee on Appropriations |
Passed |
|
| Aug 17, 2015 | Placed on suspense file | Senate Standing Committee on Appropriations |
Passed |
|
| Jul 15, 2015 | Do pass, but first be re-referred to the Committee on [Appropriations] | Senate Standing Committee on Environmental Quality |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
|
Organization
|
Position
|
Date
|
|---|---|---|
| American Cleaning Institute | ** Support | Aug 18, 2016 |
| California Chamber Of Commerce | ** Support | Aug 18, 2016 |
| California Manufacturers And Technology Association | ** Support | Aug 18, 2016 |
| California Product Stewardship Council | * Support | Jul 15, 2015 |
| California Retailers Association | ** Support | Aug 18, 2016 |
| Californians Against Waste | * Support | Jul 15, 2015 |
| Consumer Specialty Products Association | ** Support | Aug 18, 2016 |
| CVS Health | ** Support | Sep 1, 2015 |
| Industrial Environmental Association | ** Support | Aug 18, 2016 |
| National Federation of Independent Businesses | ** Support | Aug 18, 2016 |
| Rite Aid Corporation | * Support | Jul 15, 2015 |
| Walgreen Co. | * Support | Jul 15, 2015 |
Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | SB 423 |
UNFINISHED BUSINESS
Bill No: SB 423
Amended: 8/15/16
SENATE ENVIRONMENTAL QUALITY COMMITTEE: 7-0, 7/15/15
AYES: Wieckowski, Gaines, Bates, Hill, Jackson, Leno, Pavley
SENATE APPROPRIATIONS COMMITTEE: 7-0, 8/27/15
AYES: Lara, Bates, Beall, Hill, Leyva, Mendoza, Nielsen
SENATE FLOOR: 40-0, 9/1/15
AYES: Allen, Anderson, Bates, Beall, Berryhill, Block, Cannella, De León, Fuller, Gaines, Galgiani, Glazer, Hall, Hancock, Hernandez, Hertzberg, Hill, Hueso, Huff, Jackson, Lara, Leno, Leyva, Liu, McGuire, Mendoza, Mitchell, Monning, Moorlach, Morrell, Nguyen, Nielsen, Pan, Pavley, Roth, Runner, Stone, Vidak, Wieckowski, Wolk
ASSEMBLY FLOOR: 77-1, 8/18/16 - See last page for vote
SUBJECT: Surplus household consumer product waste: management
DIGEST: This bill requires the California Department of Toxic Substances Control (DTSC) to convene a Retail Waste Working Group to identify regulatory and policy directives that need clarification for managing consumer products, and adopt consensus recommendations for waste reduction opportunities.
Assembly Amendments struck provisions exempting non-prescription pharmaceutical products from the Medical Waste Management Act (MWMA).
Existing federal law:
- Authorizes, under the Food, Drug, and Cosmetic Act, the Food and Drug Administration (FDA) to oversee the safety of food, drugs, and cosmetics.
- Regulates, under the Resource Conservation and Recovery Act (RCRA) of 1976, the management of solid and hazardous wastes. In the context of pharmaceuticals, RCRA imposes strict protocols for the collection of controlled substances.
Existing state law:
- Regulates, under the Medical Waste Management Act (MWMA) which is administered by the State Department of Public Health (DPH), the management, handling, and disposal of medical waste, as defined, including pharmaceutical waste.
- Regulates, under the Hazardous Waste Control Act which is administered by the Department of Toxic Substances Control, the management, handling and disposal of hazardous waste, as defined.
This bill requires DTSC to convene a Retail Waste Working Group to identify regulatory and policy directives that need clarification for managing consumer products, and adopt consensus recommendations for waste reduction opportunities. Specifically, this bill:
- Requires DTSC to convene a Retail Waste Working Group comprised of representatives of large retailers, small retailers, district attorneys, certified unified program agencies, nongovernment organizations, local governments, other relevant state agencies as determined by DTSC, manufacturers, reverse distributors, and other stakeholders to consider and make findings and recommendations on the following:
- Regulatory and statutory requirements that may be considered confusing or may need clarification or specification when applied to the overall management by manufacturer, distributor, supplier, vendor, retail, and reverse logistics facilities of surplus household products that are wastes, including those that can be considered hazardous waste or medical waste when the waste determination is made; and,
- Consensus statutory or regulatory recommendations to facilitate and increase the liquidation, and sale of surplus household consumer products and waste reduction opportunities for those products and to clarify waste management requirements to encourage the management of surplus household products by manufacturer, distributor, supplier, vendor, retail, and reverse logistics facilities in a manner that is protective of public health and the environment.
- Defines "surplus household consumer product" as a household consumer product that cannot or will not be sold to a consumer through that product’s primary market.
- Requires, by June 1, 2017, the Retail Waste Working Group to report the findings and recommendations on the aforementioned policy issues to the Legislature.
Comments
Need for the bill. According to the author, when pharmaceuticals, other health care products, and household consumer products are not sold at an initial point of sale, the products are often processed at a reverse distribution center where the center performs various activities such as consolidation, repackaging, donation, and disposal upon completion of any of these management activities. The author states that jurisdiction over these products at the point they are considered discarded or recycled under current law, including when they are considered stored or accumulated for discard or recycling, can fall under either the MWMA or hazardous and solid waste provisions of the California Health and Safety Code. The author asserts that this dual jurisdiction has led to confusion in the regulated community.
The author states that multiple stakeholder discussions have taken place on the issues of retail waste, including over-the-counter pharmaceutical waste in California. This bill provides goals for the Retail Waste Workgroup to work towards developing consensus policy recommendations on these outstanding waste management issues in California. This will ensure both the regulators and the regulated community have a defined timeline by which agreement on these issues is to be attained.
Regulatory confusion. DTSC has authority over the management of hazardous wastes and universal wastes. The California Department of Public Health (CDPH) has authority over cosmetics, pharmaceuticals and medical waste. The Department of Resources Recycling and Recovery has authority over solid wastes.
Retail establishments argue that the various statutory and regulatory requirements of when a product becomes a waste and how it must be handled make it difficult for their employees to determine the appropriate handling of a product. Retailers argue that because of the complexity of the current regulatory scheme, they are not separating products that may be able to be donated or liquidated from those that are deemed waste if there is any question that they may be risking violation of various statutory waste handling requirements. The retailers assert that the result is a far greater than necessary rate of disposal or destruction of items that could have been retained for their useful life.
Retail Waste Workgroup. Retailers that operate stores in California and those that sell goods in California through the Internet, mail-order catalogs, door-to-door sales and other outlets are all subject to California's medical waste and/or hazardous waste laws and regulations. In an effort to clarify California's hazardous waste regulatory requirements, DTSC is gathering information and developing an understanding of hazardous waste management practices at various types of retailers.
In 2015, DTSC created a Retail Waste Workgroup to identify regulatory requirements that need clarification and to provide that clarification. The Retail Waste Workgroup consists of large and small retailers, district attorneys from multiple counties, certified unified program agency representatives, consultants, non-government organizations, CDPH and DTSC. This bill is proposing to turn the fruits of those discussions into policy recommendations for broader consumer product management by codifying the Retail Waste Working Group and establishing a date-certain for consensus policy recommendations to be made to the Legislature.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: No
According to the Assembly Appropriations Committee, enactment of this bill would result in minor, absorbable costs to DTSC.
American Cleaning Institute
American Coatings Association
California Chamber of Commerce
California Manufacturers and Technology Association
California Paint Council
California Retailers Association
Consumer Specialty Products Association
Grocery Manufacturers Association
Industrial Environmental Association
National Federation of Independent Business
Solid Waste Association of North America
OPPOSITION: (Verified 8/19/16)
None received
ASSEMBLY FLOOR: 77-1, 8/18/16
AYES: Achadjian, Alejo, Travis Allen, Arambula, Atkins, Baker, Bigelow, Bloom, Bonilla, Bonta, Brough, Brown, Burke, Calderon, Campos, Chang, Chau, Chávez, Chiu, Chu, Cooley, Cooper, Dababneh, Dahle, Daly, Dodd, Frazier, Beth Gaines, Gallagher, Cristina Garcia, Eduardo Garcia, Gatto, Gipson, Gomez, Gonzalez, Gordon, Gray, Grove, Hadley, Harper, Holden, Irwin, Jones, Jones-Sawyer, Lackey, Levine, Linder, Lopez, Low, Maienschein, Mathis, Mayes, McCarty, Medina, Melendez, Mullin, Nazarian, Obernolte, O'Donnell, Olsen, Patterson, Quirk, Ridley-Thomas, Rodriguez, Salas, Santiago, Steinorth, Mark Stone, Thurmond, Ting, Wagner, Waldron, Weber, Wilk, Williams, Wood, Rendon
NOES: Eggman
NO VOTE RECORDED: Roger Hernández, Kim
Prepared by: Rachel Machi Wagoner / E.Q. / (916) 651-4108
8/19/16 19:25:12
**** END ****
SENATE THIRD READING
STR Bill Id:SB 423
Author:(Bates)
As Amended Ver:August 15, 2016
Majority vote
SENATE VOTE: (vote not relevant)
Committee | Votes | Ayes | Noes |
Environmental Safety | 7-0 | Alejo, Dahle, Arambula, Beth Gaines, Gray, Lopez, McCarty | |
Appropriations | 15-0 | Gonzalez, Bigelow, Bloom, Bonilla, Bonta, Chang, Eggman, Eduardo Garcia, Jones, Obernolte, Quirk, Santiago, Weber, Wood, McCarty |
|
SUMMARY: Requires the California Department of Toxic Substances Control (DTSC) to convene a Retail Waste Working Group to identify regulatory and policy directives that need clarification for managing consumer products, and adopt consensus recommendations for waste reduction opportunities. Specifically, this bill:
- Requires DTSC to convene a Retail Waste Working Group comprised of representatives of large retailers, small retailers, district attorneys, certified unified program agencies, nongovernment organizations, local governments, other relevant state agencies as determined by DTSC, manufacturers, reverse distributors, and other stakeholders to consider and make findings and recommendations on the following:
- Regulatory and statutory requirements that may be considered confusing or may need clarification or specification when applied to the overall management by manufacturer, distributor, supplier, vendor, retail, and reverse logistics facilities of surplus household products that are wastes, including those that can be considered hazardous waste or medical waste when the waste determination is made; and,
- Consensus statutory or regulatory recommendations to facilitate and increase the liquidation, and sale of surplus household consumer products and waste reduction opportunities for those products and to clarify waste management requirements to encourage the management of surplus household products by manufacturer, distributor, supplier, vendor, retail, and reverse logistics facilities in a manner that is protective of public health and the environment.
- Defines "surplus household consumer product" as a household consumer product that cannot or will not be sold to a consumer through that product’s primary market.
- Requires, by June 1, 2017, the Retail Waste Working Group to report the findings and recommendations on the aforementioned policy issues to the Legislature.
FISCAL EFFECT: According to the Assembly Appropriations Committee, enactment of this bill would result in minor, absorbable costs to DTSC.
COMMENTS:
Need for the bill: According to the author, when pharmaceuticals, other health care products, and household consumer products are not sold at an initial point of sale, the products are often processed at a reverse distribution center where the center performs various activities such as consolidation, repackaging, donation, and disposal upon completion of any of these management activities. The author states that jurisdiction over these products at the point they are considered discarded or recycled under current law, including when they are considered stored or accumulated for discard or recycling, can fall under either the Medical Waste Management Act or hazardous and solid waste provisions of the California Health and Safety Code. The author asserts that this dual jurisdiction has led to confusion in the regulated community.
The author states that multiple stakeholder discussions have taken place on the issues of retail waste, including over-the-counter pharmaceutical waste in California. This bill provides goals for the Retail Waste Workgroup to work towards developing consensus policy recommendations on these outstanding waste management issues in California (CA). This will ensure both the regulators and the regulated community have a defined timeline by which agreement on these issues is to be attained.
Regulatory confusion: DTSC has authority over the management of hazardous wastes and universal wastes. The California Department of Public Health (CDPH) has authority over cosmetics, pharmaceuticals and medical waste. The Department of Resources Recycling and Recovery has authority over solid wastes.
Retail establishments argue that the various statutory and regulatory requirements of when a product becomes a waste and how it must be handled make it difficult for their employees to determine the appropriate handling of a product. Retailers argue that because of the complexity of the current regulatory scheme, they are not separating products that may be able to be donated or liquidated from those that are deemed waste if there is any question that they may be risking violation of various statutory waste handling requirements. The retailers assert that the result is a far greater than necessary rate of disposal or destruction of items that could have been retained for their useful life.
Retail Waste Workgroup: Retailers that operate stores in California and those that sell goods in California through the Internet, mail-order catalogs, door-to-door sales and other outlets are all subject to California's medical waste and/or hazardous waste laws and regulations. In an effort to clarify California's hazardous waste regulatory requirements, DTSC is gathering information and developing an understanding of hazardous waste management practices at various types of retailers.
In 2015, DTSC created a Retail Waste Workgroup to identify regulatory requirements that need clarification and to provide that clarification. The Retail Waste Workgroup consists of large and small retailers, district attorneys from multiple counties, certified unified program agency representatives, consultants, non-government organizations, CDPH and DTSC. This bill is proposing to turn the fruits of those discussions into policy recommendations for broader consumer product management by codifying the Retail Waste Working Group and establishing a date-certain for consensus policy recommendations to be made to the Legislature.
Analysis Prepared by: Paige Brokaw / E.S. & T.M. / (916) 319-3965 FN: 0004102
Date of Hearing: August 3, 2016
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Lorena Gonzalez, Chair
SBPCA Bill Id:SB 423
Author:(Bates) – As Amended Ver:August 1, 2016
Policy Committee: | Environmental Safety and Toxic Materials | Vote: | 7 - 0 |
Urgency: No State Mandated Local Program: No Reimbursable: No
SUMMARY: This bill requires the Department of Toxic Substance Control (DTSC) to convene a Retail Waste Working Group and report findings and recommendations to the Legislature by June 1, 2017. Specifically, this bill:
- Requires the task forces to be comprised of representatives of large retailers, small retailers, district attorneys, certified unified program agencies, nongovernment organizations, other relevant state agencies, manufacturers, reverse distributors, and other stakeholders.
- Requires the task force to consider and make findings and recommendations on the following:
- Regulatory and statutory requirements that may be considered confusing or may need clarification or specification when applied to the overall management, by manufacturer, distributor, supplier, vendor, retail, and reverse logistics facilities, of surplus household consumer products including products that can be considered waste or pharmaceutical when the waste determination is made.
- Statutory or regulatory recommendations to facilitate and increase the donation, liquidation, and sale of surplus household consumer products and waste reduction opportunities for those products and to clarify waste management requirements to encourage the management of surplus household consumer products, as specified.
- Defines "surplus household consumer product" as a household consumer product that cannot or will not be sold to a consumer through that product's primary market.
FISCAL EFFECT:
Minor, absorbable costs.
COMMENTS:
Purpose. Since 2013, DTSC has been regularly meeting with a group similar to the Retail Waste Working Group specified in this bill, as part of its efforts to better understand waste management activities in the retail industry. This bill proposes a slightly different scope of work to identify and clarify statutory and regulatory requirements for products eventually considered hazardous wastes.
Analysis Prepared by: Jennifer Galehouse / APPR. / (916) 319-2081
Date of Hearing: June 28, 2016
ASSEMBLY COMMITTEE ON ENVIRONMENTAL SAFETY AND TOXIC MATERIALS
Luis Alejo, Chair
SBPCA Bill Id:SB 423
Author:(Bates) – As Amended Ver:June 21, 2016
SENATE VOTE: 40-0 (vote not relevant to current version of the bill)
SUBJECT: Pharmaceutical and consumer product waste: management.
SUMMARY: Exempts non-prescription pharmaceutical products from the Medical Waste Management Act (MWMA). Specifically, this bill:
- Requires, until January 1, 2022, a pharmaceutical that is offered for sale without a prescription to be managed as hazardous waste if it meets the definition of hazardous waste.
- Requires, until January 1, 2022, a pharmaceutical that is offered for sale without a prescription, if it is not a hazardous waste, to be managed either as a medical waste or a solid waste.
- Requires the California Department of Toxic Substances Control (DTSC) to convene a Retail Waste Working Group to identify regulatory and policy directives that need clarification for managing consumer products, and adopt consensus recommendations for waste reduction opportunities.
- Requires, by March 1, 2017, the Retail Waste Working Group to identify a list of issues for discussion and resolution, and requires, by June 1, 2017, to report to the Legislature the consensus recommendations to the Legislature.
EXISTING LAW:
- Defines “drug” under the Federal Food, Drug, and Cosmetic Act as any article recognized in the official United States Pharmacopoeia, official Homoeopathic Pharmacopoeia of the United States, or official National Formulary, or any supplement to any of them. (21 United States Code Sec. 231 (g)(1))
- Establishes the MWMA to govern medical waste management at any facility where waste is generated, at transfer stations, and at treatment facilities. (Health & Safety Code (H&S) § 117600, et seq.)
- Defines "pharmaceutical waste" as a prescription or over-the-counter human or veterinary drug, including, but not limited to, a drug as defined in Section 109925 of the Federal Food, Drug, and Cosmetic Act. (H&S § 117747 (a))
- Exempts from the definition of pharmaceutical waste any pharmaceutical that is regulated pursuant to the federal Resource Conservation and Recovery Act (RCRA) or the Radiation Control Law. (H&S § 117747 (b)) Exempts from the definition of pharmaceutical waste any pharmaceutical that is being sent offsite to or by a reverse distributor for treatment and disposal by a reverse distributor that is licensed as a wholesaler of dangerous drugs. (H&S § 117690 (b)(3)(A)-(B))
- Requires, under the California Hazardous Waste Control Act (HWCA) of 1972, DTSC to regulate the appropriate handling, processing and disposal of hazardous and extremely hazardous waste to protect the public, livestock, and wildlife from hazards to health and safety. (H&S § 25100)
- Defines hazardous waste as a waste that may cause, or significantly contribute to, an increase in mortality or an increase in serious irreversible, or incapacitating reversible, illness; pose a substantial present or potential hazard to human health or the environment, due to factors including, but not limited to, carcinogenicity, acute toxicity, chronic toxicity, bioaccumulative properties, or persistence in the environment, when improperly treated, stored, transported, or disposed of, or otherwise managed. (H&S § 25141) Hazardous waste includes hazardous waste covered under RCRA. (H&S § 25117)
- Defines reverse distributor as every person who acts as an agent for pharmacies, drug wholesalers, third-party logistics providers, manufacturers, and other entities by receiving, inventorying, warehousing, and managing the disposition of outdated or non-saleable dangerous drugs. (Business & Professions Code (BP) § 4040.5)
- Authorizes the establishment of a voluntary drug repository and distribution program for the purpose of distributing surplus medications to persons in need of financial assistance to ensure access to necessary pharmaceutical therapies. (BP § 150200)
FISCAL EFFECT: Unknown. The Senate Appropriations Committee analyzed a previous version of the bill.
COMMENTS:
Need for the bill: According to the author, SB 423 is intended to build on recent California legislation that has helped to streamline the safe and efficient handling of pharmaceuticals, other health care products, and household consumer products sold by retailers in this state. The author states that when these products are not sold at an initial point of sale for various reasons, the products are often processed at a reverse distribution center where the center performs various activities such as consolidation, repackaging, donation, disposal upon completion of any of these management activities. The author further states that jurisdiction over these products at the point they are considered discarded or recycled under current law, including when they are considered stored or accumulated for discard or recycling, can fall under either the MWMA or hazardous and solid waste provisions of the Health and Safety Code. The author asserts that this dual jurisdiction has led to confusion in the regulated community and threatens to undermine positive aspects of the reverse distribution system for managing pharmaceuticals, including over-the-counter pharmaceuticals in California. The author believes that SB 423 would provide clear waste management options for over the counter pharmaceutical products by explicitly allowing these products to be scrutinized under existing hazardous waste laws when disposed rather than only the MWMA.
The author also states that multiple stakeholder discussions have taken place on the issues of retail waste, including over-the-counter pharmaceutical waste in California. DTSC created a Retail Waste Workgroup a few years ago to identify the regulatory requirements that are in need of clarification for retailers. SB 423 provides goals for the Retail Waste Workgroup to work towards developing consensus policy recommendations on these outstanding waste management issues in CA. This will ensure both the regulators and the regulated community have a defined timeline by which agreement on these issues is to be attained.
Regulating pharmaceuticals: The MWMA vests the California Department of Public Health (CDPH) with authority to regulate the generation, handling, storage, treatment, and disposal of medical waste.
Pharmaceutical wastes were added to the MWMA in 1996 (SB 1996, Wright, Chapter 536). That legislation moved the regulation of pharmaceutical waste as hazardous waste by DTSC to the Department of Healthcare Services (now the Department of Public Health) because pharmaceutical waste was not considered hazardous waste under federal law or as medical waste under the MWMA. SB 1996 did not, however, include under the definition of "pharmaceutical wastes" any pharmaceutical wastes regulated as solid waste pursuant to the California Integrated Waste Management Act.
AB 1442 (Wieckowski, Chapter 689, Statutes of 2012) excluded pharmaceuticals being sent to reverse distributors from the storage, disposal, and transport requirements of the MWMA. It also relaxed hauling requirements for pharmaceutical medical waste that is not reverse-distributed if the generator meets certain conditions. As a result, any non-saleable pharmaceutical that is returned to a licensed reverse distributor (and that is not hazardous under RCRA or radioactive under the federal Radiation Control Law) is not considered pharmaceutical or medical waste, and is therefore not regulated by the MWMA. This has the effect of allowing most non-saleable pharmaceuticals to be transferred to reverse distributors without fear of violating the strict disposal and transportation requirements for medical waste.
Regulatory confusion: Despite AB 1442, much regulatory confusion remains. DTSC has authority over hazardous materials and hazardous wastes. CDPH has authority over cosmetics, pharmaceuticals and medical waste. The Department of Resources Recycling and Recovery has authority over solid wastes and universal wastes.
According to federal and state law, a pharmaceutical is anything that contains a “drug fact” label. A drug fact label is affixed to any product that makes a health claim. These products must meet specified federal Food and Drug Administration ingredient testing, disclosure, labeling and verification of health claim requirements. This includes prescription and over-the-counter drugs as well as some consumer products that make health claims.
Retail establishments argue that the various statutory and regulatory requirements of when a product becomes a waste and how it must be handled make it difficult for their employees to determine the appropriate handling of a product. Retailers argue that because of the complexity of the current regulatory scheme, they are currently not separating products that may be able to be donated or liquidated from those that are deemed waste if there is any question that they may be risking violation of various statutory waste handling requirements. The retailers assert that the result is a far greater than necessary rate of disposal or destruction of items that could have been retained for their useful life.
Retail Waste Workgroup: Retailers that operate stores in California and those that sell goods in California through the Internet, mail-order catalogs, door-to-door sales and other outlets are all subject to California's medical waste and/or hazardous waste laws and regulations.
In an effort to clarify California's hazardous waste regulatory requirements, DTSC is gathering information and developing an understanding of hazardous waste management practices at various types of retailers.
In 2015, DTSC created a Retail Waste Workgroup to identify regulatory requirements that need clarification and to provide that clarification. The Retail Waste Workgroup consists of large and small retailers, District Attorneys from multiple counties, Certified Unified Program Agency representatives, consultants, non-government organizations, California Department of Public Health and DTSC. The most recent meeting was June 2, 2016.
The Retail Waste Workgroup is an ongoing process working through the issues for which SB 423 is raising. SB 423 is proposing to turn the fruits of those discussions into policy recommendations for broader consumer product management by codifying the Retail Waste Working Group and establishing a date-certain for consensus policy recommendations to be made to the Legislature.
The bill proposes a slightly different scope of work than the Retail Waste Workgroup is currently working on, which may narrow the goal to identify and clarify policy and regulatory requirements for products that are eventually considered hazardous wastes.
The Committee may wish to consider amending the provision of the bill codifying the Retail Waste Workgroup to clarify the intent and the goals.
Federal action to eliminate retail confusion: The US EPA has indicated that the issue of regulating the management of surplus consumer products is larger than pharmaceuticals; it has acknowledged the challenges regarding the regulation of retail hazardous waste, has provided data on retail hazardous waste generation, and has invited public comment on issues specific to retail hazardous waste.
Using 2007 census data, the US EPA identified 13 retail sectors (including vehicle service stations, electronics and appliance stores, food and beverage stores) comprising 1.6 million facilities that generate hazardous waste. Only about 41,000 (4.6%) of this total are registered as hazardous waste generators in the RCRAInfo database, which is a federal program management and inventory system about hazardous waste handlers.
It is likely that some retailers do not view themselves as hazardous waste generators who may be subject to regulation. For example, retailers may not be aware that products returned to them by the purchaser may be RCRA hazardous waste. The US EPA acknowledged the uncertainty faced by retailers in managing the wide range of retail products that may become wastes if unsold, returned, or removed from shelves for inventory changes.
Regulation of hazardous waste, including medical wastes, generated by the retail sector presents unique challenges. The retail sector handles a large number of diverse products (for example, one retailer has reported to the US EPA about a million products and 4,000 facilities nationwide), many of which may potentially become regulated as medical or hazardous waste when discarded. Thus, retailers are required to make numerous medical and hazardous waste determinations at thousands of sites, generally by store employees with limited experience with the RCRA, HWCA, or MWMA regulations.
SB 423 is proposing to ease the regulatory requirements of pharmaceuticals under the MWMA with a blanket exemption, and ease the waste determination made by retailers by offering the option of managing wastes as solid waste if the waste is not hazardous.
SB 423 does not, however, address the outstanding confusion retailers have over when a product (in this case, a pharmaceutical) is a hazardous waste.
Under the MWMA, non-RCRA pharmaceuticals are exempt. In theory, that would mean if a product is exempt from the MWMA, as it would be under SB 423, it would be treated as solid waste since it's not covered under RCRA. But, California's HWCA does not perfectly align with RCRA, and, in many cases, is more stringent. There are, in fact, many nonprescription pharmaceuticals that would have to be treated as hazardous waste. Anything that might fail DTSC's regulatory aquatic toxicity test would be a hazardous waste. Medicated shampoos, pain killers, and vitamin supplements are some examples. It is easy to understand the existing confusion over pharmaceutical product management.
What is a nonprescription pharmaceutical? The bill doesn’t define a pharmaceutical that is sold without a prescription, but it includes a broad range of products, from vitamins and supplements, pain killers, allergy and antihistamine drugs, laxatives, spermicides, anti-inflammatory drugs, cough and cold medications, steroids, anti-fungal drugs, as well as products that include anything with a chemical or pharmaceutical element, such as, but not limited to, toothpaste, medicated shampoos (dandruff, lice shampoos), mouthwash, Sun Protection Factor (SPF)-containing lotions and chap sticks, cosmetics, and any other over-the-counter drugs.
What does this bill do, exactly? SB 423 exempts all nonprescription pharmaceuticals from the MWMA and gives retailers the option of managing these pharmaceuticals, once the waste determination has been made, as either a solid waste or a medical waste, unless the pharmaceutical is hazardous waste.
This is problematic because the MWMA exists for a clear and specific reason: to manage medical waste, which includes pharmaceutical waste, in carefully specified ways to protect public health and the environment. Under the MWMA, pharmaceutical waste has to be incinerated at a permitted medical waste treatment facility; treated temperatures in excess of 1300 degrees Fahrenheit; or steam sterilized at a permitted medical waste treatment facility. (H&S § 118215)
Exempting pharmaceuticals from the MWMA would eliminate important protections we have in place to prevent pharmaceutical contamination and threats to the environment.
Contaminants of emerging concern: Our water supplies are increasingly contaminated with chemicals of concerns. Numerous contaminants, such as pharmaceuticals, personal care products (antibacterial soaps, sunscreen, bath gels, etc.), and other constituents of emerging concern, are more likely to be present in municipal wastewater than in other water sources. Although they typically exist in small concentrations, there is growing concern about the impact of constituents of emerging concern, and other unregulated compounds, on public health and the environment. By allowing OTC pharmaceuticals to be treated as solid waste, this bill would be creating a greater risk of pharmaceutical contamination in our water supplies, thus exacerbating the conundrum of contaminants of emerging concern.
Committee amendments: Given the policy concerns around the changes to the MWMA the bill is proposing, the Committee may wish to consider the following amendments:
Strike Sections 1, 2 and 3 from the bill, entirely.
Clarify the goals of the Retail Waste Working Group to be more consistent with the current goals of the Working Group and the US EPA's efforts to clarify policy requirements for managing consumer products that are considered hazardous waste at the time of disposal. This amendments would be drafted as follows:
(a) The Department of Toxic Substances Control shall convene a Retail Waste Working Group comprised of representatives of large retailers, small retailers, district attorneys, certified unified program agencies, nongovernment organizations, State Department of Public Health, manufacturers, other relevant state agencies as determined by DTSC, reverse distributors, and other stakeholders to do both of the following to consider and make recommendations on the following:
IdentifyRegulatory and policydirectivesrequirements that may be considered confusing, and/or may need clarification or specification when applied to the overall management of consumer products that are wastes, including those that are considered hazardous when the waste determination is made.- Adopt consensus policy and/or regulatory recommendations to facilitate and increase
sustainable practices andwaste reduction opportunities for consumer products and clarify hazardous waste management in the retail industry to encourage safe and efficient options for managingthe flow ofwaste and surplus household consumer productsthrough the reverse supply chain.
(b) By March 1, 2017 June 1, 2017, the Retail Waste Working Group shall identify a list of issues for discussion and resolution and, thereafter, shall meet regularly to assist and advise the Legislature, and shall report the consensus recommendations to the Legislature by June 1, 2017.
REGISTERED SUPPORT / OPPOSITION:
Support
American Cleaning Institute
California Chamber of Commerce
California Manufacturers and Technology Association
California Retailers Association
Consumer Specialty Products Association
Industrial Environmental Association
National Federation of Independent Businesses
Opposition
None on file
Analysis Prepared by: Paige Brokaw / E.S. & T.M. / (916) 319-3965
SB 423
Page 5
|
Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 |
THIRD READING
Bill No: SB 423
Amended: 8/31/15
SENATE ENVIRONMENTAL QUALITY COMMITTEE: 7-0, 7/15/15
AYES: Wieckowski, Gaines, Bates, Hill, Jackson, Leno, Pavley
SENATE APPROPRIATIONS COMMITTEE: 7-0, 8/27/15
AYES: Lara, Bates, Beall, Hill, Leyva, Mendoza, Nielsen
SUBJECT: Retail nonprescription surplus products: determinations for reuse
DIGEST: This bill establishes a process for the handling and management of retail nonprescription pharmaceutical surplus products.
Existing federal law:
Authorizes, under the Food, Drug, and Cosmetic Act, the Food and Drug Administration (FDA), to oversee the safety of food, drugs, and cosmetics.
Regulates, under the Resource Conservation and Recovery Act (RCRA) of 1976, the management of solid and hazardous wastes. In the context of pharmaceuticals, RCRA imposes strict protocols for the collection of controlled substances.
Existing state law:
Provides that under the Medical Waste Management Act (MWMA), administered by the State Department of Public Health:
Regulates the management, handling, and disposal of medical waste, as defined, including pharmaceutical waste.
Defines “pharmaceutical waste” as any pharmaceutical that for any reason may no longer be sold or dispensed for use as a drug and excludes from this definition those pharmaceuticals that still have potential value to the generator because they are being returned to a reverse distributor for possible manufacturer credit.
Defines “pharmaceutical” as a prescription or over-the-counter human or veterinary drug including, but not limited to, a drug as defined in the Sherman Food, Drug and Cosmetic Law or the Federal Food, Drug, and Cosmetic Act. “Pharmaceutical” does not include any pharmaceutical that is regulated pursuant to either RCRA or the Radiation Control Law; and certain items, such as household waste, are specifically excluded from the definition of medical waste.
Specifies that waste comprised only of pharmaceuticals is hazardous, and is considered “medical waste,” although it is not subject to hazardous waste laws, as specified.
Provides that under the Hazardous Waste Control Act (HWCA), administered by the Department of Toxic Substances Control (DTSC), regulates the management, handling and disposal of hazardous waste, as defined.
This bill:
Establishes, until January 1, 2022, criteria to be followed for the handling and management of retail nonprescription pharmaceutical surplus products, as defined, if a reasonable determination for reuse has been made or when a reasonable determination for reuse cannot be made but the product has been recalled as required by law.
Authorizes DTSC to adopt regulations as deemed necessary to establish standards for the proper and safe handling of retail nonprescription pharmaceutical surplus products.
Specifies that a facility that elects to follow the procedures in this bill is not subject to regulation of specified products by the MWMA.
Declares the urgency of this statute.
Background
Risks of pharmaceuticals in the environment. A study conducted by the United States Geological Survey (USGS) from 1999-2000 sampled 139 streams across 30 states and found that 80% had measurable concentrations of both prescription and nonprescription drugs, steroids, and reproductive hormones. Since the USGS released its report in 2002, a number of studies have demonstrated the low-level presence of pharmaceutical agents throughout the environment and water supply.
While
the human effects of pharmaceutical agents in the environment are not
fully understood, harm to aquatic organisms and ecosystems due to low
levels of pharmaceutical agents are clearly established.
As California further explores the re-utilization of water through water recycling, prevention of contamination becomes crucial to prevent public health exposure through water.
Health risks associated with incineration. Incinerators are known to release numerous toxic chemicals into the atmosphere and to produce ashes and other solid waste residues that contaminate the air, water and soil as well as vegetation in the vicinity of the facility. Adverse health effects associated with incineration are of great concern as large population groups and workers may be exposed to derived toxic substances. Many of these chemicals are known to be persistent, bioaccumulative, carcinogenic or endocrine disruptors.
Populations
living near incinerators are potentially exposed to chemicals by way
of inhalation of contaminated air, consumption of contaminated foods,
water or dermal contact with contaminated soil. Additionally, there
are occupational hazards for incinerator workers.
Comments
The confusion over “pharmaceutical waste.” According to federal and California law, a pharmaceutical is anything that contains a “drug fact” label. A drug fact label is affixed to any product that makes a health claim. These products must meet specified FDA ingredient testing, disclosure, labeling and verification of health claim requirements. This includes prescription and over-the-counter drugs as well as some consumer products that make health claims, such as sunscreen, toothpastes, mouthwashes or lotions that contain sunscreen.
Pharmaceuticals are medical waste and are required to be managed under MWMA, which is designed to ensure that medical waste does not enter the environment and does not present a risk to public health.
However, toothpaste, mouthwashes, lotions and other over-the-counter products that do not contain drug facts are not medical waste. Depending on their characteristics and risks posed they must be handled pursuant to either hazardous or solid waste statutes, as defined and specified.
Retail establishments argue that the various statutory and regulatory requirements of when a product becomes a waste and how it must be handled make it difficult for their employees to determine the appropriate handling. Additionally, MWMA requires that medical waste be incinerated. The retailers argue that because of the complexity of the current regulatory scheme, they are currently not separating products that may be able to be donated or liquidated from those that are deemed waste if there is any question that they may instead be required to be disposed of, in order to ensure that they don’t violate the various statutory waste handling requirements. The retailers assert that the result is a far greater than necessary rate of disposal/incineration of items that could have been retained for their useful life.
Striking a balance. MWMA, HWCA and other state and federal waste laws have specific requirements for handling, transportation and disposal to protect public health and the environment. When alternative management standards are adopted, the standards are narrowly crafted and contain specific conditions for tracking, handling, transportation and disposal to accommodate the unique nature of the wastestream. SB 423 recognizes the public policy benefit of diverting more waste and crafts an alternative management scheme that provides some flexibility within the statute for the point at which this category of items is determined to be a waste. While it is important in providing this flexibility, it is equally important that it be balanced with appropriate tracking and accountability to ensure safe handling and enforceability of the statute.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: Yes
According to the Senate Appropriations Committee this bill will have unknown costs to the Hazardous Waste Control Account for DTSC to “register” specified entities.
California Retailers Association
CVS Health
OPPOSITION: (Verified 8/27/15)
None received
Prepared by: Rachel Machi Wagoner / E.Q. / (916) 651-4108
8/30/15 19:48:52
**** END ****
SB 423 (Bates) Page 0 of 1
SENATE COMMITTEE ON APPROPRIATIONS
Senator Ricardo Lara, Chair
2015 - 2016 Regular Session
SB 423 (Bates) - Retail nonprescription surplus products: determinations for reuse.
|
|
Version: July 6, 2015 |
Policy Vote: E.Q. 7 - 0 |
Urgency: Yes |
Mandate: Yes |
Hearing Date: August 27, 2015 |
Consultant: Marie Liu |
*********** ANALYSIS ADDENDUM – SUSPENSE FILE ***********
The following information is revised to reflect amendments
adopted by the committee on August 27, 2015
Bill Summary:
AB 423 would establish a process for the handling and management of retail nonprescription pharmaceutical surplus products.
Fiscal Impact:
Unknown costs to the Hazardous Waste Control Account (special) for the Department of Toxic Substances Control (DTSC) to “register” specified entities
Author Amendments:
Clarify the roles of the Department of Public Health and DTSC
Specify that a facility that elects to follow the procedures in this bill are not subject to regulation of specified products by the Medical Waste Management Act.
-- END --
SB 423 (Bates) Page 2 of 2
SENATE COMMITTEE ON APPROPRIATIONS
Senator Ricardo Lara, Chair
2015 - 2016 Regular Session
SB 423 (Bates) - Retail nonprescription surplus products: determinations for reuse
|
|
Version: July 6, 2015 |
Policy Vote: E.Q. 7 - 0 |
Urgency: Yes |
Mandate: Yes |
Hearing Date: August 17, 2015 |
Consultant: Marie Liu |
This bill meets the criteria for referral to the Suspense File.
Bill Summary:
AB 423 would establish a process for the handling and management of retail nonprescription pharmaceutical surplus products.
Fiscal Impact:
Unknown costs to the Hazardous Waste Control Account (special) to the Department of Toxic Substances Control (DTSC) to permit additional new transfer stations.
Unknown potential costs to the Hazardous Waste Control Account (special) to DTSC to develop necessary regulations.
Background:
The Department of Public Health (DPH) regulates the management, handing, and disposal of medical waste under the Medical Waste Management Act. Medical waste includes pharmaceutical waste, which under federal and California law is any product that includes a “drug fact” label that is affixed to any product that makes a health claim. This definition includes some consumer products that make health claims, such as sunscreen, toothpaste, mouthwash, or lotions.
DTSC regulates the management, handling, and disposal of hazardous waste, as defined, in accordance with the Hazardous Waste Control Act.
Proposed Law:
This bill would establish a handling and management process for retail nonprescription pharmaceutical surplus products. This process would require the product to be transported to a reverse distributor or a reverse distribution center for evaluation, liquidation, donation, or transfer back to a manufacturer or supplier. The product must be transported with a tracking document that identifies specific information including the UPC label and the name and contact information of the generator.
The reverse distributor or reverse distribution center would be required to maintain tracking documents for three years, submit a hazardous materials business plan, and be licensed by the California State Board of Pharmacy as a wholesaler of dangers drugs. The reverse distributor would also be required to be permitted by DTSC as a transfer station and registered by DTSC as a hazardous waste generator, transfer facility, or storage facility.
This process would only apply to a pharmaceutical that may be sold without a prescription and has been either determined to be eligible for reuse by a waste generator or is a recalled product. A pharmaceutical that is eligible for reuse would be defined as a product that is in unadulterated packaging, in a condition suitable for resale, and not designated for disposal.
Staff Comments:
This bill authorizes DTSC to develop regulations to implement this new waste management process for nonprescription pharmaceuticals. At this time DTSC does not know the universe of products to which this bill may apply and whether any of these products can be considered hazardous. Depending on the size and characteristics of the products that could follow the process created by this bill, DTSC may need regulations of unknown complexity or none at all.
The new handling and management process established by this bill may prompt more facilities seeking to be permitted by DTSC as a transfer station in order to comply with the bill’s requirement. A straightforward transfer station permit typically takes $156,000 in staff time to review and process. However, the permit fee is only between $8,500 and $50,600, with the balance of the costs being covered by the Hazardous Waste Control Act. Depending on the number of facilities that would seek permitting by DTSC, which is unknown, costs could be minor to the millions of dollars. Staff notes that DTSC currently has a significant backload in addressing permit applications. The additional facilities seeking permitting to comply with this bill could potentially exasperate this backlog. Staff notes that DPH also permits transfer stations and it may be the author’s intent that this requirement is in reference to DPH’s permits.
This bill also requires that a reverse distributor be “registered” with the DTSC as a hazardous waste generator, transfer facility, or storage facility. It is unclear the cost implications of this provision as transfer and storage facilities are “permitted” and hazardous waste generators are neither “registered” or “permitted.” Staff recommends that this bill be clarified.
-- END --
SB 423 (Bates) Page 7 of 7
SENATE COMMITTEE ON ENVIRONMENTAL QUALITY
Senator Wieckowski, Chair
2015 - 2016 Regular
Bill No: SB 423
Author: |
Bates |
||
Version: |
7/6/2015 |
Hearing Date: |
7/15/2015 |
Urgency: |
Yes |
Fiscal: |
Yes |
Consultant: |
Rachel Machi Wagoner |
||
SUBJECT: Retail nonprescription surplus products: determinations for reuse.
ANALYSIS:
Existing federal law:
Under the Food, Drug, and Cosmetic Act, the Food and Drug Administration (FDA) is authorized to oversee the safety of food, drugs, and cosmetics.
Under the Resource Conservation and Recovery Act (RCRA) of 1976, the management of solid and hazardous wastes is regulated. In the context of pharmaceuticals, RCRA imposes strict protocols for the collection of controlled substances.
Existing state law:
Under the Medical Waste Management Act (MWMA), administered by the State Department of Public Health (DPH),
Regulates the management, handling, and disposal of medical waste, as defined, including pharmaceutical waste.
Defines “pharmaceutical” as a prescription or over-the-counter human or veterinary drug including, but not limited to, a drug as defined in the Sherman Food, Drug and Cosmetic Law or the Federal Food, Drug, and Cosmetic Act. “Pharmaceutical” does not include any pharmaceutical that is regulated pursuant to either RCRA or the Radiation Control Law; and certain items, such as household waste, are specifically excluded from the definition of medical waste.
Defines “pharmaceutical waste” as any pharmaceutical that for any reason may no longer be sold or dispensed for use as a drug and excludes from this definition those pharmaceuticals that still have potential value to the generator because they are being returned to a reverse distributor for possible manufacturer credit.
Specifies that waste comprised only of pharmaceuticals is hazardous, and is considered “medical waste,” although it is not subject to hazardous waste laws, as specified.
Under the Hazardous Waste Control Act (HWCA), administered by the Department of Toxic Substances Control, regulates the management, handling and disposal of hazardous waste, as defined.
This bill:
Until January 1, 2022, would establish criteria to be followed for the handling and management of retail nonprescription pharmaceutical surplus products, as defined, if a reasonable determination for reuse has been made or when a reasonable determination for reuse cannot be made but the product has been recalled as required by law.
Authorizes DTSC to adopt regulations as deemed necessary to establish standards for the proper and safe handling of retail nonprescription pharmaceutical surplus products.
Declares the urgency of this statute.
Background
Risks of pharmaceuticals in the environment. A study conducted by the United States Geological Survey (USGS) from 1999-2000 sampled 139 streams across 30 states and found that 80% had measurable concentrations of both prescription and nonprescription drugs, steroids, and reproductive hormones. Since the USGS released its report in 2002, a number of studies have demonstrated the low-level presence of pharmaceutical agents throughout the environment and water supply.
While
the human effects of pharmaceutical agents in the environment are not
fully understood, harm to aquatic organisms and ecosystems due to low
levels of pharmaceutical agents are clearly established.
As California further explores the re-utilization of water through water recycling, prevention of contamination becomes crucial to prevent public health exposure through water.
Health risks associated with incineration. Incinerators are known to release numerous toxic chemicals into the atmosphere and to produce ashes and other solid waste residues that contaminate the air, water and soil as well as vegetation in the vicinity of the facility. Adverse health effects associated with incineration are of great concern as large population groups and workers may be exposed to derived toxic substances. Many of these chemicals are known to be persistent, bioaccumulative, carcinogenic or endocrine disruptors.
Populations
living near incinerators are potentially exposed to chemicals by way
of inhalation of contaminated air, consumption of contaminated foods,
water or dermal contact with contaminated soil. Additionally, there
are occupational hazards for incinerator workers.
Comments
Purpose of Bill. According to the author, SB 423 is intended to build on recent California legislation that has helped to streamline the safe and efficient handling of pharmaceuticals, other health care products, and household consumer products sold by retailers in this state. The author states that when these products are not sold at an initial point of sale for various reasons, the products are often processed at a reverse distribution center where the center performs various activities such as consolidation, repackaging, donation, disposal upon completion of any of these management activities. The author further states that jurisdiction over these products at the point they are considered discarded or recycled under current law, including when they are considered stored or accumulated for discard or recycling, can fall under either the California Medical Waste Management Act or hazardous and solid waste provisions of the Health and Safety Code. The author asserts that this dual jurisdiction has led to confusion in the regulated community and threatens to undermine positive aspects of the reverse distribution system for managing pharmaceuticals, including over-the-counter pharmaceuticals and household consumer products in California.
The author states that multiple stakeholder discussions have taken place on the issues of retail waste, including over-the-counter pharmaceutical waste in California. The author believes that SB 423 would provide waste management options that would reconcile the confusion over dual jurisdiction by providing a unified waste management option for the over-the-counter pharmaceuticals.
The confusion over “pharmaceutical waste.” According to federal and California law, a pharmaceutical is anything that contains a “drug fact” label. A drug fact label is affixed to any product that makes a health claim. These products must meet specified federal Food and Drug Administration ingredient testing, disclosure, labeling and verification of health claim requirements. This includes prescription and over-the-counter drugs as well as some consumer products that make health claims, such as sunscreen, toothpastes, mouthwashes or lotions that contain sunscreen.
Pharmaceuticals are medical waste and are required to be managed under MWMA, which is designed to ensure that medical waste does not enter the environment and does not present a risk to public health.
However, toothpaste, mouthwashes, lotions and other over-the-counter products that do not contain drug facts are not medical waste. Depending on their characteristics and risks posed they must be handled pursuant to either hazardous or solid waste statutes, as defined and specified.
Retail establishments argue that the various statutory and regulatory requirements of when a product becomes a waste and how it must be handled make it difficult for their employees to determine the appropriate handling. Additionally, MWMA requires that medical waste be incinerated. The retailers argue that because of the complexity of the current regulatory scheme, they are currently not separating products that may be able to be donated or liquidated from those that are deemed waste if there is any question that they may instead be required to be disposed of, in order to ensure that they don’t violate the various statutory waste handling requirements. The retailers assert that the result is a far greater than necessary rate of disposal/incineration of items that could have been retained for their useful life.
Striking a balance. MWMA, HWCA and other state and federal waste laws have specific requirements for handling, transportation and disposal to protect public health and the environment. When alternative management standards are adopted, the standards are narrowly crafted and contain specific conditions for tracking, handling, transportation and disposal to accommodate the unique nature of the wastestream. SB 423 recognizes the public policy benefit of diverting more waste and crafts an alternative management scheme that provides some flexibility within the statute for the point at which this category of items is determined to be a waste. While it is important in providing this flexibility, it is equally important that it be balanced with appropriate tracking and accountability to ensure safe handling and enforceability of the statute.
Does this bill indicate (again) a need to reform MWMA for pharmaceutical waste? The California Legislature has heard bills each year reforming the MWMA for the management concerning the reuse of unused prescription drugs, transport of unused prescription drugs from retails, take-back of prescription drug waste for disposal, take back and disposal of sharps waste. Is this bill further indication that MWMA needs to be reformed to better accommodate pharmaceutical waste?
Related/Prior Legislation
SB 1014 (Jackson, 2014) would have required a producer of a pharmaceutical sold in this state, individually or through a stewardship organization, to submit a plan to CalRecycle by January 1, 2015. The plan would have needed to provide for the development of a program to collect, transport, and process home-generated pharmaceutical drugs and to include specified aspects, including the minimum amount of collection sites, including by January 1, 2016, at least one collection service within 10 miles per person in the state.
AB 1442 (Wieckowski, Chapter 689, Statutes of 2012) defines pharmaceutical waste for purposes of the Medical Waste Management Act, and exempts a pharmaceutical waste generator or parent organization that employs health care professionals who generate pharmaceutical waste from specified medical waste hauling requirements if the generator, health care professional, or parent organization retains specified documentation and meets specified requirements and if the facility receiving the medical waste retains specified documentation and meets specified requirements. This bill also authorizes pharmaceutical waste to be transported by the generator or health care professional who generated the pharmaceutical waste, a staff member of the generator or health care professional, or common carrier, as defined, pursuant to these provisions.
SOURCE:
California Retailers Association
SUPPORT:
CVSHealth
OPPOSITION:
None received
ARGUMENTS IN SUPPORT:
Proponents for SB 423 state their support for SB 423 but have concerns where they seek additional amendments:
The purpose of SB 423 is to add a new provision of the Health and Safety Code, relating to the reverse distribution of unsold household consumer products, and to amend the California Medical Waste Management Act (Act) to provide an alternative management option for unsold non-prescription drugs. SB 423 is needed to address regulatory confusion under current law regarding reverse distribution and strengthen environmental protection programs at retail facilities in California. This legislation could potentially create an opportunity for waste minimization by chain drug stores and others that manage large volumes of unsold consumer products and non-prescription drugs, also known as over-the-counter pharmaceuticals (OTCs).
Current law can be read to require that all unsold consumer products are potential solid, hazardous, or medical wastes at retail locations unless the retailer knows with certainty at the store that the product can be reused for its intended purpose or reclaimed by thousands of original manufacturers. The timing of this knowledge does not match typical retail processes that rely on reverse distribution to consolidate products for business purposes, including potential donation, sale to third-party liquidators, and waste minimization, prior to any decision to discard the products. Further, and related to this product management, the Act can be read to require that OTCs must be managed and incinerated as medical waste.
Currently, recycling or waste minimization is not an option for OTCs because the Act can be read to mandate incineration. Mandatory incineration for OTCs is excessive and contrary to good environmental stewardship where there may be other options for managing these products when they can no longer be sold to the public.
Primary areas for further discussion should the bill move forward include:
Regarding generator knowledge, retailers do not know at retail locations whether a product will be donated or liquidated. The role of the reverse distributor is to help direct the products for reuse or return to the manufacturer, manufacturer’s agent or vendor. Thus, so long as the retail location does not know that the ultimate disposition of the product will be disposal, and the product is in a condition that it can be reused, we trust this is sufficient knowledge by the retailer to qualify for the option.
Regarding licensing for reverse distributors and reverse distribution centers, further clarification is needed to know whether there is flexibility on these requirements because reverse distributors under SB 423 should not need the same licensing as those facilities under AB 1442 that are accepting prescription and dangerous drugs for disposal.
Regarding transportation requirements, because retailers will be shipping surplus products back in a manner like the products are shipped to stores, we trust that the packaging and transportation requirements for surplus product shipments can match as close as possible current safe and secure transport practices that must meet the requirements of other laws.
Regarding product tracking requirements, we would hope to rely on current shipping documentation such as bills of lading to track surplus products. Because these shipments are valuable to retailers for credit, tax purposes and inventory, documentation exists today to track these shipments that could be used for purposes of SB 423. We trust there is flexibility on this point as well.
-- END --
Discussed in Hearing
Assembly Floor
Senate Floor
Senate Standing Committee on Environmental Quality
Bill Author
Bill Co-Author(s):